The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Progenitor cells from which all blood cells derive.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed)
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
Transplantation of an individual's own tissue from one site to another site.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Providing an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Compassionate use trials allow patients to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called expanded access trial.
A CXC chemokine that is chemotactic for T-LYMPHOCYTES and MONOCYTES. It has specificity for CXCR4 RECEPTORS. Two isoforms of CXCL12 are produced by alternative mRNA splicing.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
A particular zone of tissue composed of a specialized microenvironment where stem cells are retained in a undifferentiated, self-renewable state.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
CXCR receptors with specificity for CXCL12 CHEMOKINE. The receptors may play a role in HEMATOPOIESIS regulation and can also function as coreceptors for the HUMAN IMMUNODEFICIENCY VIRUS.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Cells with high proliferative and self renewal capacities derived from adults.
Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Proteins prepared by recombinant DNA technology.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Cells that can give rise to cells of the three different GERM LAYERS.
Specialized stem cells that are committed to give rise to cells that have a particular function; examples are MYOBLASTS; MYELOID PROGENITOR CELLS; and skin stem cells. (Stem Cells: A Primer [Internet]. Bethesda (MD): National Institutes of Health (US); 2000 May [cited 2002 Apr 5]. Available from: http://www.nih.gov/news/stemcell/primer.htm)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
An anti-inflammatory 9-fluoro-glucocorticoid.
The blood-making organs and tissues, principally the bone marrow and lymph nodes.

Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. (1/889)

Intensive chemotherapy given in early chronic phase of chronic myelogenous leukemia (CML) has resulted in high numbers of circulating Philadelphia (Ph) chromosome-negative hematopoietic progenitor cells (HPC). We have autografted 30 consecutive patients with CML in chronic phase with HPC collected in this way to facilitate restoration of Ph-negative hematopoiesis in bone marrow after high-dose therapy. Hematopoietic recovery to greater than 0.5 x10(9)/L neutrophils and to greater than 25 x 10(9)/L platelets occurred in all patients, a median of 13 (range, 9 to 32) days and 16 (range, 6 to 106) days postautograft, respectively. Regenerating marrow cells were Ph-negative in 16 (53%) patients and greater than 66% Ph-negative in 10 (33%) patients. Twenty-eight patients are alive 6 to 76 months (median, 24 months) after autografting. Three patients have developed blast crisis from which 2 have died. Eight patients are in complete cytogenetic remission at a median of 20 (range, 6 to 44) months with a median ratio BCR-ABL/ABL of 0.002 (range, <0.001 to 0.01). Eight patients are in major cytogenetic remission at a median of 22 (range, 6 to 48) months. No patient died as a consequence of the treatment. All patients had some degree of stomatitis that was severe in 15 (50%) patients. Gastrointestinal and hepatic toxicities were observed in about one fourth of patients. Thus, autografting with Ph-negative mobilized HPC can result in prolonged restoration of Ph-negative hematopoiesis for some patients with CML; moreover, most autograft recipients report normal or near normal activity levels, suggesting that this procedure need not to be associated either with prolonged convalescence or with chronic debility.  (+info)

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. (2/889)

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). Two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of CD34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of CD13, CD33, CD38, HLA-DR and Thy-1 antigens on CD34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. Three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the blocking beta2 integrin monoclonal antibody caused a reduction of CD34+ cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34+ cells correlates with a poor adhesion to BM stroma; CD34+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (3/889)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. (4/889)

To determine the effect of G-CSF administration on both the total number of CD34+ cells and the primitive CD34+ subsets in bone marrow (BM), we have analyzed BM samples serially obtained from 10 normal donors in steady-state and during G-CSF treatment. Filgrastim was administered subcutaneously at a dosage of 10 microg/kg/day (n = 7) or 10 microg/kg/12 h (n = 3) for 4 consecutive days. Peripheral blood sampling and BM aspirates were performed on day 1 (just before G-CSF administration), day 3 (after 2 days of G-CSF), and day 5 (after 4 days of G-CSF). During G-CSF administration, a significant increase in the total number of BM nucleated cells was observed. The percentage (range) of CD34+ cells decreased in BM from a median of 0.88 (0.47-1.44) on day 1 to 0.57 (0.32-1.87), and to 0.42 (0.16-0.87) on days 3 and 5, respectively. We observed a slight increase in the total number of BM CD34+ cells on day 3 (0.66 x 10(9)/l (0.13-0.77)), and a decrease on day 5 (0.23 x 10(9)/l (0.06-1.23)) as compared with steady-state (0.40 x 10(9)/l (0.06-1.68)). The proportion of primitive BM hematopoietic progenitor cells (CD34+CD38-, CD34+HLA-DR-, CD34+CD117-) decreased during G-CSF administration. In parallel, a significant increase in the total number of CD34+ cells in peripheral blood was observed, achieving the maximum value on day 5. These results suggest that in normal subjects the administration of G-CSF for 5 days may reduce the number of progenitor cells in BM, particularly the most primitive ones.  (+info)

Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. (5/889)

In these studies, we compared the phenotype, function, and expression of type 1, type 2, and monocyte-associated cytokine mRNA transcripts in autologous bone marrow (BM) and growth factor-mobilized peripheral blood stem cell (PSC) products. These studies demonstrate that lymphocytes and monocytes in stem cell products are abnormally activated, expressing significantly higher levels of interleukin (IL)-2, 4 and 10, interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha), but not IL-8, as compared to normal peripheral blood mononuclear cells (PBMC). In addition, the levels of IL-2, IL-10 and TNF-alpha are significantly higher in mobilized PSC as compared to BM products. The high cytokine levels are unexpected as T cell function in stem cell products is depressed. PSC products have high levels of T cell inhibitory activity, which directly correlates with IL-10 expression, both of which are mechanisms that might be involved in the immune dysfunction within stem cell products used for autologous stem cell transplantation. These data demonstrate that: (1) immune cells in autologous BM and PSC products are activated with the expression of high levels of type 1 and type 2 cytokines as well as monokines; (2) PSC products contain a high frequency of monocytes which mediate T cell inhibitory activity; and (3) despite the high levels of cytokine expression, T cell function in stem cell products is depressed. The significance of these immune abnormalities within stem cell products for myeloid and lymphoid recovery following autologous stem cell transplantation remains to be determined.  (+info)

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. (6/889)

This study compares the immune properties of peripheral blood stem cell (PSC) products mobilized with different hematopoietic growth factors (HGFs) as well as apheresis products and peripheral blood leukocytes (PBL) from normal individuals. We found that monocytes in mobilized PSC products appear to inhibit T cell function independent of whether granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) was used for mobilization. In addition, the GF used to mobilize the stem cell product may be less important to the CD4:CD8 ratio than the extent of prior chemotherapy, as we found an inverse correlation between chemotherapy and the CD4:CD8 ratio. In other observations, all apheresis products, whether mobilized or unmobilized, contained significantly more monocytes compared to normal PBL. The mononuclear cells (MNC) from G-CSF or GM-CSF mobilized PSC products had a similar T cell phytohemagglutinin (PHA) mitogenic response that was significantly lower (P = 0.001 and P = 0.005, respectively) than non-mobilized apheresis products. We also examined the T cell inhibitor (TI) activity of the MNC from the PSC products for allogeneic lymphocyte proliferation and found that PSC products significantly reduced the proliferation of allogeneic PBL to PHA. A significant correlation (P = 0.001, r = 0.517) between the frequency of monocytes and TI activity also was observed.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (7/889)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (8/889)

We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.  (+info)

The short-term goals of this protocol is to demonstrate that subjects with new-onset T1DM undergoing autologous hematopoietic stem cell mobilization and
TY - JOUR. T1 - Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. AU - Basak, Grzegorz W.. AU - Jaksic, Ozren. AU - Koristek, Zdenek. AU - Mikala, Gabor. AU - Basic-Kinda, Sandra. AU - Mayer, Jiri. AU - Masszi, Tamas. AU - Giebel, Sebastian. AU - Labar, Boris. AU - Wiktor-Jedrzejczak, Wieslaw. PY - 2011/6/1. Y1 - 2011/6/1. N2 - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the ...
BACKGROUND/AIMS: Peripheral blood stem cells (PBSC) are one of the most promising stem cell sources for treatment of ischaemic heart disease. However, the experience of mobilisation and collection of PBSC using granulocyte-colony stimulating factor (G-CSF) in patients with myocardial infarction (MI) is still limited. We report our experiences with the feasibility and safety of collection of mobilised PBSC with G-CSF in MI patients, and the influence of acute ischaemia on efficacy of PBSC collection.. METHODS: 74 patients with acute or old myocardial infarction (AMI vs OMI, n = 46 and n = 28) underwent PBSC collection after administration of G-CSF twice a day at a dose of 5 microg/kg for 3 days. Flow cytometric analysis of cell surface markers was performed.. RESULTS: No evidence of inflammation or ischaemia was observed during G-CSF mobilisation and PBSC collection. The yield of CD34(+) cells was 12.9 (SD 15.92) x10(9)/l (5.04% (5.30%) of total cells) with a product volume of 37.9 (8.4) ml after ...
Our results demonstrate that STZ-treated diabetic mice show a similar impairment in the G-CSF-induced mobilization of HSPCs to that observed in humans and that this defect is not the consequence of reduced bone marrow HSPC content or an intrinsic HSPC defect. Rather, the data support a model in which cells of the microenvironment are perturbed in diabetes and lose their ability to modulate CXCL12 expression in response to specific stimuli. Altered CXCL12 expression may blunt HSPC release from the bone marrow and can be overcome by direct pharmacological inhibition of the interaction of CXCL12 with its CXCR4 receptor.. The preservation or increase in HSPC numbers we observed is in contrast to recent reports of reduced LSK cells in diabetic mice (37, 38). These differences may reflect species differences or the long-term consequences of diabetes disease, which we did not assess in this study. All mice used in our experiments were ,12 weeks of age. For the STZ model, animals were analyzed 5 to 8 ...
This study will investigate the efficacy and tolerability of bortezomib + cyclophosphamide + filgrastim or lenograstim in patients with multiple myeloma. The
In this study, we demonstrated a novel function of IL-33 that can be exploited to obtain HSPCs for stem cell transplantation. Our results indicate that vessel endothelial cells were the cellular targets of IL-33 and might be responsible for HSPC mobilization through CCL7, based on the following observations. First, CCL7 was the most markedly increased in serum, compared with BM plasma, among chemokines known to mobilize HSPCs after IL-33 injection (Fig. 4B). Second, vessel endothelial cells in the BM produced CCL7, and aortic fragments did so in response to IL-33 (Fig. 4A, 4B). Third, IL-33-treated mouse serum or conditioned medium of aortic fragment culture was able to induce the migration of LK cells in a CCR2-dependent manner (Fig. 4C, 5C). Finally, neutralization of CCL7 completely blocked IL-33-mediated HSPC mobilization (Fig. 5E).. The CXCL2-CXCR2 axis is involved in hematopoietic stem cell mobilization and its homing and engraftment (29). Even though CXCL2 was detected in serum after ...
MAIN RESULTS: We identified four RCTs fitting the inclusion criteria. However, two of these closed prematurely due to low recruitment and did not report results. The remaining two trials evaluated 600 participants with multiple myeloma or non-Hodgkin lymphoma. In both studies the experimental group received G-CSF plus plerixafor and the control group received G-CSF plus placebo.The meta-analysis showed no evidence for differences between plerixafor and placebo group regarding mortality at 12 months (600 participants; risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.69; P = 1.00; moderate-quality evidence) and adverse events during stem cell mobilisation and collection (593 participants; RR 1.02, 95% CI 0.99 to 1.06; P = 0.19; high-quality evidence).Regarding the outcome successful stem cell collection, the meta-analysis showed an advantage for those participants randomised to the plerixafor group (600 participants; RR 2.42, 95% CI 1.98 to 2.96; P , 0.00001; high-quality evidence).As ...
...Putnam Valley NY. (June 19 2014) Researchers in Taiwan have found t...The study will be published in a future issue of Cell Transplantat... Currently OA treatment involves the use of anti-inflammatory drugs ...While the beneficial effects of G-CSF-mobilized peripheral blood stem ...,Stem,cell,mobilization,therapy,may,effectively,treat,osteoarthritis,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Stem cell mobilization: After completion of the mononuclear cell apheresis procedure, all patients are offered DT-PACE chemotherapy for cytoreduction and stem cell mobilization. This regimen is as follows: dexamethasone once daily for 4 days; thalidomide once daily for 4 days; cisplatin IV continuously over 4 days (patients with serum creatinine levels ≥ 2.0 mg/dL do not receive cisplatin); doxorubicin hydrochloride IV continuously over 4 days; cyclophosphamide IV continuously over 4 days; etoposide IV continuously over 4 days. Patients also receive filgrastim (G-CSF) SC once daily starting on the day after completion of chemotherapy. An acceptable alternative for stem cell mobilization is to use cyclophosphamide IV over 12 hours or, for patients who require that outpatient stem cell mobilization procedures be performed, cyclophosphamide IV over 2 hours. The cyclophosphamide mobilization regimen should be used if the patient has already received DTPACE as part of the pre-transplant therapy ...
CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission.7,11 Furthermore, CD303 (BDCA-2) antibodies were used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization8 or transplantation10 . CD303 (BDCA-2) antibodies were also used for immunohistochemical staining, for example to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases.5,12,13 Clone AC144 recognizes the the CD303 (BDCA-2) antigen1,3 which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow) and non-lymphoid tissue.3,6 Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker.1-11 CD303 (BDCA-2)+ plasmacytoid
CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission. Furthermore, CD303 (BDCA-2) antibodies have been used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization or transplantation. CD303 (BDCA-2) antibodies have also been used for immunohistochemical staining, for example, to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases. Clone REA693 recognizes the CD303 (BDCA-2) antigen which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow), and non-lymphoid tissue. Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker. CD303 (BDCA-2)+ plasmacytoid dendritic cells in
Patients with advanced or treatment-refractory Multiple Myeloma (MM), Hodgkins Disease (HD) and Non-Hodgkins Lymphoma (NHL) may be successfully treated with high dose chemotherapy followed by autologous transplantation of peripheral blood stem cells (PBSCs). Successful engraftment of peripheral blood stem cells (PBSCs) is well correlated with the number of CD34+ cells infused.. Stem cell collection with plerixafor could have a major benefit by increasing the circulating number of PBSCs and decreasing the number of apheresis sessions required to collect a sufficient number of PBSCs for transplant.. This is a multi-centre, open label, single-arm study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received more than one autologous or any allogeneic stem cell transplant are not eligible.. Screening for eligibility will take place up to 30 days before ...
Grace M. Niemiro, Justin Parel, Joseph Beals, Stephan van Vliet, Scott A. Paluska, Daniel R. Moore, Nicholas A. Burd, Michael De Lisio Kinetics of circulating progenitor cell mobilization during submaximal exercise J Appl Physiol 122: 675-682, 2017; DOI: 10.1152/japplphysiol.00936.2016. ...
Free Online Library: India has adequate number of healthcare professionals, study finds. by Asian News International; News, opinion and commentary General interest Medical personnel Reports Research Surveys
High-dose chemotherapy with autologous stem cell support is the current standard procedure in the first-line treatment in younger patients with myeloma
Stem cell mobilization represents a transient increase in the levels of circulating stem and progenitor cells. In Stem Cell Mobilization: Methods in Protocols , expert researchers in the field detail cell mobilization methodology and recent developments in the field for basic and biomedical research community.
What is G-CSF? Granulocyte Colony Stimulating Factor Glycoprotein Growth factor Cytokine Produced by endothelium, macrophages and other immune cells G-CSF receptor present on precursor cells in the bone marrow Initiates proliferation and differentiation into mature granulocytes Stimulates bone marrow cell release into circulation
SAMP10マウスにおける運動によるアディポネクチン/AdipoR1活性化を介した筋幹細胞動員・再生能力および筋代謝変化の回 ...
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
Read about how a new method for stem cell mobilization allows doctors to gather stem cells for a transplant in 15 minutes after a single injection.
Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
Two previous studies described a close dependence of CPC mobilization on NO generation. Aicher and colleagues21 showed that eNOS−/− mice exhibit reduced VEGF-induced mobilization of CPCs. Intravenous infusion of wild-type PCs rescued the defective neovascularization of eNOS−/− mice in a model of hindlimb ischemia. Recently, Laufs and colleagues10 measured the increase in circulating CPCs after ET in wild-type and eNOS−/− mice. Because changes in CPC count were absent in eNOS−/− mice in response to exercise, those authors hypothesized that NO would be an important mediator for CPC release.. We have previously documented that endothelial function is systemically improved after systemic ET in patients with CAD by flow-mediated increases of eNOS expression and activity,3 leading to an increased NO bioavailability. In the present trial, patients with CAD who met the inclusion criteria of the study exercised under the same condition. Therefore, it can be assumed that eNOS expression ...
In this issue, Singh et al. set out to decipher the mechanism by which CD26 relays G-CSF-induced HSPC mobilization (16, 17). This was achieved by performing sophisticated experiments to determine the extent to which CD26 expression by hematopoietic cells or by stromal cells in the BM microenvironment is essential for the stem cell mobilization process (1). Contrary to the prior hypothesis suggesting that CXCL12 cleavage by hematopoietic CD26 promotes HSPC migration out of the BM, Singh and colleagues showed that hematopoietic expression of CD26 is not essential for HSPC mobilization. Moreover, CD26 expression was reduced in mobilized HSPCs, and deletion of CD26 in murine HSPCs did not alter HSPC mobilization in a WT environment (1). These unexpected results align with recent reports indicating that CD26 truncates inflammatory cytokines into a nonactive form (18, 19) and, as such, may interfere with the hematopoietic response during alert and stress conditions. However, CD26 expression by niche ...
Tables follow) About BioLineRx BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRxs current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial scheduled for completion in mid-2015; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for ...
This function is designed to handle the production task of a standard PDF process. It is designed to build using pdflatex (unless otherwise specified) an adequate number of times to enable full typesetting to occur after taking into account items like contents pages, glossaries, and figures.
Struggle to keep an adequate number of cops on the streets amid a historically rapid outflow has spurred department to make an unprecedented move
TY - JOUR. T1 - Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning. T2 - The effect of postgrafting mycophenolate mofetil dosing. AU - Maris, Michael B.. AU - Sandmaier, Brenda M.. AU - Storer, Barry E.. AU - Maloney, David G.. AU - Shizuru, Judith A.. AU - Agura, Edward. AU - Kliem, Constanze. AU - Pulsipher, Michael. AU - Maziarz, Richard T.. AU - McSweeney, Peter A.. AU - Wade, James. AU - Langston, Amelia A.. AU - Chauncey, Thomas R.. AU - Bruno, Benedetto. AU - Blume, Karl G.. AU - Storb, Rainer. PY - 2006/4/1. Y1 - 2006/4/1. N2 - We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m2, 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg ...
TY - JOUR. T1 - Successful Stem Cell Remobilization Using Plerixafor (Mozobil) Plus Granulocyte Colony-Stimulating Factor in Patients with Non-Hodgkin Lymphoma. T2 - Results from the Plerixafor NHL Phase 3 Study Rescue Protocol. AU - Micallef, Ivana N.. AU - Stiff, Patrick J.. AU - DiPersio, John F.. AU - Maziarz, Richard T.. AU - McCarty, John M.. AU - Bridger, Gary. AU - Calandra, Gary. N1 - Funding Information: Financial disclosure: This study was wholly supported by research funding from Genzyme Corporation. The authors thank Sachin Marulkar, Genzyme Corporation, for statistical support and Andrew Dye and Pritesh Gandhi, Genzyme Corporation, for help with the content and coordination of manuscript revisions. P.J.S. and R.T.M. received research funding and honoraria from Genzyme Corporation. I.N.M. received research funding from Genzyme Corporation. J.F.D. received honoraria from Genzyme Corporation. J.M. received honoraria and research funding from Genzyme Corporation and Celgene ...
TY - JOUR. T1 - A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. AU - Pradhan, Kamnesh R.. AU - Johnson, Cynthia S.. AU - Vik, Terry A.. AU - Sender, Leonard S.. AU - Kreissman, Susan G.. PY - 2006/6/1. Y1 - 2006/6/1. N2 - Objective. To determine the feasibility, toxicities, and the response rate (RR) of a dose intensive, submyeloablative, induction chemotherapy protocol termed EPiC (etoposide, carboplatin, and intensive cyclophosphamide) utilizing sequential peripheral blood stem cell (PBSC) collection and infusion as hematopoietic support in children with newly diagnosed Stage 4 neuroblastoma. Patients and Methods. Twenty-five children (age ,1 year) with Stage 4 neuroblastoma were enrolled. First and third cycles consisted of cyclophosphamide (4 gm/m 2) and carboplatin (400 mg/m 2). Second and fourth cycles consisted of carboplatin (1 gm/m 2), and etoposide (450 mg/m 2). PBSC were ...
TY - JOUR. T1 - Proteolytic enzyme levels are increased during granulocyte colony-stimulating factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. AU - Van Os, R. AU - Van Schie, MLJ. AU - Willemze, R. AU - Fibbe, WE. PY - 2004/7. Y1 - 2004/7. N2 - Previous studies from our laboratory indicate that functional, mature neutrophils are essential for interleukin-8 (IL-8)-induced stem cell mobilization. To study a possible role of neutrophils in granulocyte colony-stimulating factor (G-CSF) induced hematopoietic mobilization, we assessed the number of circulating CD34(+) cells in healthy allogeneic stem cell donors on days 3, 4, and 5 of mobilization for comparison with the number of peripheral blood neutrophils and the plasma levels of IL-8, Flt3 ligand (FL), matrix metalloproteinase-9 (MMP-9), and human neutrophil elastase (HNE). Thirty-seven of 45 donors required 1 day of apheresis to obtain 5 x 10(6) CD34(+)/kg recipient body ...
Hematopoietic progenitor cells (HPCs) normally reside in the bone marrow (BM) but can be mobilized into the peripheral blood (PB) after treatment with GCSF or chemotherapy. In previous studies, we showed that granulocyte precursors accumulate in the BM during mobilization induced by either GCSF or cyclophosphamide (CY), leading to the accumulation of active neutrophil proteases in this tissue. We now report that mobilization of HPCs by GCSF coincides in vivo with the cleavage of the N-terminus of the chemokine receptor CXCR4 on HPCs resident in the BM and mobilized into the PB. This cleavage of CXCR4 on mobilized HPCs results in the loss of chemotaxis in response to the CXCR4 ligand, the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12). Furthermore, the concentration of SDF-1 decreased in vivo in the BM of mobilized mice, and this decrease coincided with the accumulation of serine proteases able to directly cleave and inactivate SDF-1. Since both SDF-1 and its receptor, CXCR4, are ...
Abstract Background: In Ireland the use of spinal mobilisation therapy (SMT) is a relatively new field in the management of pain in acute and chronic onset of low back pain (LBP) as individuals seek alternatives to
Our preliminary results suggest the existence of quantitative and qualitative differences in immune cells and type1 and type2 cytokines between granulocyte colony-stimulating factor (G-CSF) primed bone marrow (G-BM) and G-CSF-mobilized peripheral blood grafts (G-PB). Our findings suggest that lower T-cell hyporesponsiveness and easier polarization of T cells from Th1 to Th2 are found in G-BM. ...
3.0.CO;2-H. PMID 9210707. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (September 2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 356 (9232): 802-7. doi:10.1016/S0140-6736(00)02654-4. PMID 11022927. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y (June 2002). Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin. Cancer Res. 8 (6): 1767-71. PMID 12060615. Li K, Li CK, Chuen CK, Tsang KS, Fok TF, James AE, Lee SM, Shing MM, Chik KW, Yuen PM (February 2005). Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy. Eur. J. Haematol. 74 (2): 128-35. doi:10.1111/j.1600-0609.2004.00343.x. PMID 15654904. Järvinen R, ...
TY - JOUR. T1 - Differential gene expression underlying the functional distinctions of primary human CD34+ hematopoietic stem and progenitor cells from peripheral blood and bone marrow. AU - Steidl, Ulrich G.. AU - Kronenwett, Ralf. AU - Haas, Rainer. PY - 2003. Y1 - 2003. N2 - The restorative capacity of human CD34+ hematopoietic cells is clinically used in the autologous and allogeneic transplant setting to support cytotoxic therapy. We examined gene expression patterns of highly enriched bone marrow CD34+ (BM-CD34+) or G-CSF-mobilized peripheral blood CD34+ (PB-CD34+) cells by cDNA array technology, quantitative real-time RT-PCR, and flow cytometry, to identify molecular causes underlying the functional differences between circulating and sedentary hematopoietic stem and progenitor cells. The greater cell cycle and DNA synthesis activity of BM-CD34+ compared to PB-CD34+ cells was reflected by the 2- to 5-fold higher expression of 9 genes involved in cell cycle, 11 genes regulating DNA ...
Stroncek DF, Shaw BE, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, ODonnell PV, Hale GA, Defilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA. Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34Yields Are Less. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2018 Jan 0; 24(1):175-184. Epub 2017 Sep 25. 12/2/2017 ...
Hematopoietic stem and progenitor cells (HSPCs) mobilized from the bone marrow to the peripheral blood by granulocyte colony‐stimulating factor (G‐CSF) are widely used for stem cell transplantation and have advantages over traditional bone marrow-derived HSPCs. This review provides an overview of the events that underlie HSPC mobilization and addresses the relevant cellular and molecular components of the bone marrow niche from which the HPSCs are mobilized from.
Your doctor will provide you with detailed instructions about the administration of Mozobil (plerixafor injection) for your stem cell mobilization.
Review current Neonatal Screening strategies and stem cell collection at this study day at The University of Salford, ONECPD, Manchester.
PI: H. Geiger. Trauma results in mobilisation of bone marrow residing stem cells, including haematopoietic, mesenchy-mal and endothelial stem cells. There is evidence that such endogenously mobilized stem cells or exoge-nously provided stem cells are beneficial in trauma therapy. Mechanisms and biological importance though of trauma-induced endogenous mobilisation have not been investigated in great detail, precluding further rationale approaches for using stem cell mobilisation for the treatment of traumatic injuries. We hypothesize that distinct stem cell populations (haematopoietic, endothelial and mesenchymal) are mobi-lized upon trauma by distinct but also unique biological mechanisms and contribute significantly to regen-eration of trauma injury. In this proposal we will determine the extent of mobilisation of distinct stem cell populations in response to trauma, investigate the underlying mechanism of mobilisation and the extent of the therapeutic benefit of spontaneous but also induced ...
Each month, birth certificate information is used to generate a list of Connecticut women who have delivered a live born infant instate within the past two to six months. From this list, approximately 200 women per month are randomly selected to participate in the survey. Addressing racial and ethnic disparities is an overarching priority for programs within the Connecticut DPH. Staff within DPHs Community, Family Health and Prevention Section (CFHPS) are actively working to both understand and address the marked and persistent perinatal disparities that exist for particular racial and ethnic groups in Connecticut. As such, ensuring there is an adequate number of responses from affected racial and ethnic groups of interest are critical for analysis. Women from certain racial and ethnic groups are sampled at a higher rate because some groups experience more pregnancy-related problems. Oversampling ensures that an adequate number of responses are attained to allow for meaningful analyses to ...
Jim Cole, SonicLife, Best Sine Wave Exercise for Whole Body Atraumatically, eGFT Top Delivery of DNA Song of Life Mineral epiGenetic Resonance to Open Genetics for Healing and Regeneration, Stem Cell Mobilization and Support, CBD Nanotech Liposomal Cannabidiol Oil, Antiinflammatory, Immunomodulatory, Anti-Anxiety, Anti-Stress, Anti-Cancer, Dr Bill Deagle MD, NutriMedical Report, www.NutriMedical.com, www.ClayandIRON.com, www.Deagle-Network.com, Cannabidiol CMD… ...
Straka, C.; Hebart, H.; Adler-Reichel, S.; Werding, N.; Emmerich, B. und Einsele, H. (2003): Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma. In: Oncology, Nr. 2: S. 94-98 [PDF, 71kB] ...
Be Natural Organics has received the lowest toxicity ratings from The Compact for Safe Cosmetics, a leading U.S. health and environmental agency dedicated to protecting the health and safety of consumers. Our low ratings demonstrate the cleanliness of our products ...
Processing autologous mobilized peripheral blood progenitor cells (PBPC) collected by leukapheresis to reduce RBC, platelets and granulocytes in the final PBPC product.
Star performers by no means think theyve identified check out this site a Mobilizer right until that individual has proved it along with her steps. Stars ordinarily ask stakeholders they think could be Mobilizers to put in place a gathering with essential selection makers or to offer info obtainable only by actively investigating an issue or conferring with colleagues. A person star performer from a worldwide telecommunications enterprise defined to us that she usually assessments what her consumer contacts convey to her theyre able to do ...
Here is a letter written by a beginner! The writer has not used adequate number of connectors. Look at the common connectors and combine 2 or more short sentences into one. Have a look, below, at the list connectors you can use and you should not use. 23 April, 1990 Ms Rae Willis The Community […] More. ...
One of the most recent issues Dr. Panny has worked tirelessly on deals with the length of hospital stays for new mothers. By the mid-1990s hospital stays for new mothers had gone from an average three days to just one, a result largely due to increasing cost pressures on hospitals.9 After much debate and lobbying, the Maryland legislature became the first to pass the 48-Hour Bill, which would ensure that mothers and newborns would receive adequate medical care in the first two days after delivery. Dr. Susan Panny was instrumental in both the local and national efforts because she provided data to the U.S. Congress and assisted in crafting the national legislation which passed in 1997.10 Another significant cause Dr. Panny devotes her energies to deals with ensuring that adequate numbers of tests for newborns are performed to screen for hereditary disorders and abnormalities. In 2001, Maryland doctors only tested newborns for eight diseases that could cause mental retardation, deafness or ...
Emphasis is given on clinical studies Preclinical experiences have been shared Adequate number of illustrations are provided in the book for easier
Phooey. Most likely there will be no stem cell harvest tomorrow. The doctor came in while I was getting chemo (Rituxan) this morning and said my white cell count is at its nadir (lowest point) right now. He thinks it will be a couple of days before it rebounds. Ive been doing the Neupogen shots since last week, but nothing keeps you from bottoming out after chemo. Ill have to go back to the hospital early every morning to check my white cell count, and when it reaches the proper level, they will keep me for the stem cell harvest. ...
Mayack, S. R.; Wagers, A. J. (2 May 2008). "Osteolineage niche cells initiate hematopoietic stem cell mobilization". Blood. 112 ... She has also identified novel regulators (such as EGR1) of stem cell trafficking and stem cell number in bone marrow and during ... Wagers researches intrinsic and extrinsic regulators of stem cell function and how stem cells impact tissue regeneration and ... and principal faculty of the Harvard Stem Cell Institute. She is co-Chair of the Department of Stem Cells and Regenerative ...
hematopoietic system G-CSF is also a potent inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the ... of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell ... Tay J, Levesque JP, Winkler IG (December 2016). "Cellular players of hematopoietic stem cell mobilization in the bone marrow ... G-CSF may also be given to the receiver in hematopoietic stem cell transplantation, to compensate for conditioning regimens. ...
"Current developments in mobilization of hematopoietic stem and progenitor cells and their interaction with nicehes in bone ... Lapidot T, Petit I (September 2012). "Current understanding of stem cell mobilization: the roles of chemokines, proteolytic ... Besides liver cells, A1PI is produced in bone marrow, by lymphocytic and monocytic cells in lymphoid tissue, and by the Paneth ... In addition to binding to neutrophil elastase released by inflammatory cells, A1AT also binds to elastase localized on the cell ...
"Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced ... with expression on most immature and mature hematopoietic cell types (e.g. neutrophils, monocytes, T and B cells, dendritic ... some B cells (B lymphocytes) and NK cells] and is highly induced following cell activation. There are two isoforms, CXCR3-A and ... Langerhans cells and macrophages). In addition, CXCR4 can also be found on vascular endothelial cells and neuronal/nerve cells ...
"Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced ... is secreted by monocytes and macrophages and is chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. The ... CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. CXCL2, like related chemokines, is ... A study was published in 2013 testing the role of CXCL2, CXCL3, and CXCL1 in the migration of airway smooth muscle cells (ASMCs ...
... hematopoietic stem cells into the bloodstream as peripheral blood stem cells. Peripheral blood stem cell mobilization is very ... CXCR4's ligand SDF-1 is known to be important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem ... It is a very efficient inducer of hematopoietic stem cell mobilization in animal and human studies. In a small human clinical ... To LB, Levesque JP, Herbert KE (October 2011). "How I treat patients who mobilize hematopoietic stem cells poorly". Blood. 118 ...
Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is ... are important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence. The in vivo ... inducer of mobilization of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood stem cells. ... is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are ...
Isolation of Haematopoetic stem cells: Rector K, Liu Y, Van Zant G (2013). "Comprehensive hematopoietic stem cell isolation ... Isolation of Mesenchymal stem cells: Yosupov N, Haimov H, Juodzbalys G (2017). "Mobilization, Isolation and Characterization of ... Isolated cells can also be used for cell culture, in which a single cell multiplies to create a colony of cells. Cell isolation ... Circulating cells such as blood cells or some tumour cells can be isolated by taking a blood sample. As blood samples contain a ...
Mobilization is used clinically as a source of hematopoietic stem cells for hematopoietic stem cell transplantation (HSCT). ... KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of ... It is also a marker for mouse prostate stem cells. In addition, mast cells, melanocytes in the skin, and interstitial cells of ... the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells ...
... cells. It also induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to ... B cells and T cells)) by activating the hematopoietic progenitors. It acts by binding to and activating FLT3 (CD135) which is ... In strains of plasmodium, FLT3L was shown to be released from mast cells and cause the expansion of dendritic cells, leading to ... FLT3L is crucial for steady-state plasmacytoid dendritic cell (pDC) and classical dendritic cell (cDC) development. A lack of ...
Nervi B, Link DC, DiPersio JF (October 2006). "Cytokines and hematopoietic stem cell mobilization". J. Cell. Biochem. 99 (3): ... SCF may serve as guidance cues that direct hematopoietic stem cells (HSCs) to their stem cell niche (the microenvironment in ... c-Kit is expressed in HSCs, mast cells, melanocytes, and germ cells. It is also expressed in hematopoietic progenitor cells ... promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division". Blood. 86 (5): 1757-64. doi: ...
"Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle". Cell Stem ... mobilization and senescence are detrimental elements. These detrimental effects will eventually cause apoptosis. There are also ... have reviewed evidence that age-dependent accumulation of DNA damage in both stem cells and cells that comprise the stem cell ... for stem cell dysfunction with aging. Hematopoietic stem cells (HSCs) regenerate the blood system throughout life and maintain ...
2005). "Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist". J. ... "Regulation of the HIF-1α level is essential for hematopoietic stem cells". Cell Stem Cell. 7 (3): 391-402. doi:10.1016/j.stem. ... 2010). "The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche". Cell Stem Cell ... immune cells, and even platelets all originate from the same progenitor cell, the hematopoietic stem cell (HSC). As these cells ...
... injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later ... mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683-91. doi:10.1038/sj.bmt ... It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell ... Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to ...
... to mobilize hematopoietic stem cells). BL-8040 is a CXCR4 antagonist that has undergone clinical trials (e.g. in various ... June 2016 BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed ... BL-8040 treatment enhanced anti-tumor immune response potentially by increasing the CD8+ T-cells in the tumor microenvironment ... to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells". Journal of Clinical ...
Not to be confused with Endothelial stem cell.. Endothelial progenitor cell (or EPC) is a term that has been applied to ... are cells believed to give rise to both the endothelial and hematopoietic systems during early development. Angioblasts are ... the miRNAs miR-10b and miR-196b led to significant defects in angiogenesis-mediated tumor growth by decreasing the mobilization ... Endothelial colony forming cell[edit]. Endothelial colony forming cells are a late outgrowth cell type; that is, they are only ...
"Generation of Engraftable Hematopoietic Stem Cells from Induced Pluripotent Stem Cells by Way of Teratoma Formation". Molecular ... improvement of heart function due to mobilization and redirection of epicardial progenitor cells toward cardiovascular cell ... Scientists develop 'game changing' stem cell repair system. Stem Cells Portal Could this new stem cell become the game changer ... "Human Somatic Cell Nuclear Transfer Using Adult Cells". Cell Stem Cell. 14 (6): 777-780. doi:10.1016/j.stem.2014.03.015. PMID ...
Hematopoietic stem cells were cultured (see cell culture) on a so-called semisolid matrix, which prevents cells from moving ... Promegapoietin Bone marrow stimulation Stem cell mobilization Alberts, Bruce; et al. (2002). Molecular Biology of the Cell (4th ... These are referred to as "colonies". Therefore, it was possible to add various substances to cultures of hemopoietic stem cells ... all of the cells derived from it will remain clustered around the spot in the matrix where the first cell was originally ...
SDF-1α secreted from Mesenchymal Stem Cells (MSCs) has important role in homing and maintenance of Hematopoietic Stem Cell (HSC ... is also certain degree of similarity in homing-mobilization of normal stem cells and metastasis-invasion of cancer stem cells. ... cell-cell interactions between stem cells, as well as interactions between stem cells and neighbouring differentiated cells, ... The CSC niche is very similar to normal stem cells niche (embryonic stem cell (ESC), Adult Stem Cell ASC) in function ( ...
... a multipotent hematopoietic stem cell, becomes a common myeloid progenitor or a multipotent stem cell, and then a unipotent ... It appears that this links erythropoietin-driven eyrthropoiesis with the iron mobilization needed for hemoglobin synthesis. ... Erythropoiesis is the development of mature red blood cells from erythropoietic stem cells. The first cell that is ... There are colony forming units that the cells follow during their formation. These cells are referred to as the committed cells ...
The adipocytes in this depot are derived from mesenchymal stem cells (MSC) which can give rise to fat cells, bone cells as well ... is a poorly understood adipose depot that resides in the bone and is interspersed with hematopoietic cells as well as bony ... R, Ross; J, Rissanen (November 1994). "Mobilization of Visceral and Subcutaneous Adipose Tissue in Response to Energy ... February 2010). "Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells". ...
The only prospect for a permanent cure is the high-risk option of an allogeneic hematopoietic stem cell transplantation (SCT). ... Martino R, Sureda A, Brunet S (1997). "Peripheral blood stem cell mobilization in refractory autoimmune Evans syndrome: a ... Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK (2001). "Allogeneic stem cell transplantation for Evans syndrome". ... The symptoms of Evans syndrome vary between patients depending on which blood cells are affected. If red blood cells are ...
Bone marrow or hematopoietic stem cell transplant (41.1) Puncture of spleen (41.2) Splenotomy (41.3) Diagnostic procedures on ... Stapes mobilization (19.1) Stapedectomy (19.2) Revision of stapedectomy (19.3) Other operations on ossicular chain (19.4) ... Magnetic resonance imaging of brain and brain stem (88.92) Magnetic resonance imaging of chest and myocardium (88.93) Magnetic ... 1 bacterial smear 2 culture 3 culture and sensitivity 4 parasitology 5 toxicology 6 cell block and Papanicolaou smear 9 other ...
... is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of ... Imitola is highly cited for his work in neural stem cells migration. The mechanisms of how neural stem cells migrate to injury ... creating Injury induced stem cell niches elucidated by reporter stem cells, as proposed by Professor Evan Y. Snyder to denote ... the impact of inflammation in the endogenous neural stem cell in multiple sclerosis, and the ethical implications of stem cell ...
... growth factors and mobilization of peripheral blood derived stem cells for blood and marrow transplant. Her professional ... Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in humans, ... Mobilization of peripheral blood progenitor cells by chemotherapy and GM-CSF for hematologic support after high dose ... hematopoietins and stem cells (three editions), Molecular Targeting in Oncology). Antman's publications also include reviews ...
Studies in rhesus monkeys suggest that the enzyme is involved in IL-8-induced mobilization of hematopoietic progenitor cells ... "Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand". Cell. 109 ( ... "Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leukemia & Lymphoma. 43 (2): 233-41. doi: ... Lastly, there is significant evidence that Gelatinase B is required for the recruitment of endothelial stem cells, a critical ...
Muse cells do not express CD34 (markers for hematopoietic stem cells, adipose stem cells, VSELs) and CD117 (hematopoietic stem ... "Mobilization of Pluripotent Multilineage-Differentiating Stress-Enduring Cells in Ischemic Stroke". Journal of Stroke and ... bone marrow-mesenchymal stem cells and adipose-derived stem cells. Muse cells are able to generate cells representative of all ... When mesenchymal cells (sometimes called mesenchymal stem cells) are separated into Muse and non-Muse cells by SSEA-3 cell ...
TILs have a common origin with myelogenous cells at the hematopoietic stem cell, but diverge in development. Concentration is ... December 2010). "Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes ... March 2014). "Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients". Proceedings of the ... T cells reach tumor sites via the circulatory system. The TME appears to preferentially recruit other immune cells over T cells ...
"Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and ... the use of low amplitude high velocity joint mobilization together with exercise improves lung function and exercise capacity.[ ... "Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell ... "Harnessing the potential of lung stem cells for regenerative medicine". The International Journal of Biochemistry & Cell ...
hematopoietic system. G-CSF is also a potent inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into ... Stem cell transplantsEdit. G-CSF may also be given to the receiver in hematopoietic stem cell transplantation, to compensate ... of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell ... Tay J, Levesque JP, Winkler IG (December 2016). "Cellular players of hematopoietic stem cell mobilization in the bone marrow ...
Activated c-kit is then able to recruit hematopoietic, endothelial and mast cell progenitor cells, these cells are then ... Rafii, S; Lyden, D (2003). "Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration". ... promotes tissue revascularization through VEGF release from mast cells and MMP-9 mediated progenitor cell mobilization". J. Exp ... Cathepsins also can be secreted by cells, associate with the cell surface, and degrade the ECM. A study of all 11 members of ...
The word *ɸloud-io- is thought to be the origin of Proto-Germanic *bliwa- (which also means "lead"), from which stemmed the ... Lead-based semiconductors such as lead telluride and lead selenide are used in photovoltaic cells and infrared detectors. Lead ... In animals, lead exhibits toxicity in many organs, damaging the nervous, renal, reproductive, hematopoietic, and cardiovascular ... and mobilization of previously buried lead. Elevated concentrations of lead persist in soils and sediments in post-industrial ...
... cord blood stem cell transplantation MeSH E04.936.225.687.500 - hematopoietic stem cell transplantation MeSH E04.936.225.687. ... stapes mobilization MeSH E04.580.450.873 - tympanoplasty MeSH E04.580.515 - pharyngectomy MeSH E04.580.540 - pharyngostomy MeSH ... 625 - mesenchymal stem cell transplantation MeSH E04.936.225.687.750 - peripheral blood stem cell transplantation MeSH E04.936. ... cell transplantation MeSH E04.936.225.375 - islets of langerhans transplantation MeSH E04.936.225.687 - stem cell ...
... rapidly and efficiently mobilizes blood stem cells from the bone marrow into the bloodstream in mice, researchers report ... October 10th in the journal Stem Cell Reports. ... Single-Day Hematopoietic Stem Cell Mobilization. Stem Cell ... Hematopoietic stem cell transplantation, which replaces abnormal blood-forming stem cells with healthy cells, is a curative ... multipotent hematopoietic stem cells, suggesting that this approach may be suitable for hematopoietic stem cell transplantation ...
Y. Gazitt, "Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, ... I. G. Winkler and J.-P. Lévesque, "Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells ... A. Gratwohl, H. Baldomero, O. Schmid et al., "Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in ... Besides the technical difficulty of precisely determining stem cell mobilization, an increase in stem cells can take place in ...
EMH activation requires hematopoietic stem cell (HSC) proliferation and mobilization, processes that depend upon estrogen ... 27-Hydroxycholesterol induces hematopoietic stem cell mobilization and extramedullary hematopoiesis during pregnancy. ... 27-Hydroxycholesterol induces hematopoietic stem cell mobilization and extramedullary hematopoiesis during pregnancy. ... During pregnancy, 27HC levels increased in hematopoietic stem/progenitor cells as a result of CYP27A1, a cholesterol ...
"Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced ... "Dynamic cellular phenotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced ... Dynamic cellular phenotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced ... Dynamic cellular phenotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced ...
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem ... Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2(4):356- ... SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. ... cell cycling. (A) Cell-cycling status of the marrow LSK cells and CD150+CD48−LSKs hematopoietic stem cells (HSCs) was ...
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or ... Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or ... Hematopoietic progenitor cells (HPCs) normally reside in the bone marrow (BM) but can be mobilized into the peripheral blood ( ... We now report that mobilization of HPCs by GCSF coincides in vivo with the cleavage of the N-terminus of the chemokine receptor ...
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1). The safety and scientific validity of this study is ...
Peripheral blood cell mobilization and hematopoietic stem cell transplantation. To induce HSPC mobilization, mice were i.p. ... hematopoietic stem cell transplantation. HSPC. hematopoietic stem and progenitor cell. KO. knockout. PMN. polymorphonuclear ... IL-33-Induced Hematopoietic Stem and Progenitor Cell Mobilization Depends upon CCR2. Juyang Kim, Wonyoung Kim, Hongnga T. Le, U ... IL-33 induced hematopoietic stem and progenitor cell (HSPC) mobilization and extramedullary hematopoiesis. HSPC mobilization ...
The mechanisms of BM hematopoietic stem/progenitor cell (HSPC) adhesion, engraftment, and mobilization remain incompletely ... and mobilization of mouse hematopoietic stem/progenitor cells. ... and mobilization of mouse hematopoietic stem/progenitor cells. ... During mobilization, MuPAR was inactivated by plasmin via proteolytic cleavage. Cell-autonomous loss of the gene encoding MuPAR ... marks a subset of HSPCs and promotes the preservation of the size of this pool of cells in the BM. Loss or inhibition of MuPAR ...
... factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. In: ... factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. Van ... factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. / ... factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. ...
... biological response modifiers and the family of cell adhesion-promoting molecules. ... cells (c), and hematopoietic stem cells (e) by cytofluorometry. Identification panel of hematopoietic stem cells (Lineage-7AAD− ... erythroid cells (b), lineage− cells (c), and hematopoietic stem cells (d) by cytofluorometry. Data are mean ± SEM from 3 ... J. L. Abkowitz, A. E. Robinson, S. Kale, M. W. Long, and J. Chen, "Mobilization of hematopoietic stem cells during homeostasis ...
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell ... 3102 Investigators, Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell ... Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. ... Diabetes Impairs Hematopoietic Stem Cell Mobilization by Altering Niche Function Message Subject. (Your Name) has forwarded a ...
Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood. 2008;112(3):519-531.. Blood 2012 119:1793; doi: ... Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood. 2008;112(3):519-531.. Blood, 119(7), 1793. ... Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood. 2008;112(3):519-531. ... Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood. 2008;112(3):519-531. ...
Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell (2012). 11(2 ... Stem cell mobilization viewed in the clinical context. HSPC mobilization remains an instrumental part of stem cell ... Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell (2012). 10(5), 520-530. Article ... Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell (2008). 3(4), 364-366. ...
990 Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in ... Patients with severe sickle cell disease (SCD) may benefit from β-globin gene transfer into autologous hematopoietic stem cells ... PB-derived CD34+ cells may contain lower proportions of lineage-committed CD34+ cells than BM-derived cells from patients with ... these cells mobilize at low rates. CD34+ cell yields from BM harvest (BMH) are typically lower than those after mobilization ...
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell ... into the peripheral blood for collection by leukapheresis for hematopoietic stem cell transplant (HSCT). The FDA-approved ... CAR T cells produce complete responses in T-cell malignancies Publish date: January 7, 2020 ... 103 cells/uL on day 4 of filgrastim or tbo-filgrastim mobilization for allogeneic transplantation and the use of plerixafor in ...
... was conducted to assess the efficacy and safety of plerixafor for the mobilization and collection of haematopoietic stem cells ... Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in ... Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients ... Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous ...
Function of Jam-B/Jam-C interaction in homing and mobilization of human and mouse hematopoietic stem and progenitor cells. ... Stem Cells. 2013 Dec 19. doi: 10.1002/stem.1624. [Epub ahead of print] ...
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. In: Journal of Experimental Medicine. ... Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. Journal of Experimental Medicine. 2011 ... Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. Kana Miyamoto, Shigeyuki Yoshida, Miyuri ... title = "Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization",. author = "Kana Miyamoto and ...
"Hematopoietic Stem Cell Mobilization" by people in this website by year, and whether "Hematopoietic Stem Cell Mobilization" was ... Hematopoietic Stem Cell Mobilization*Hematopoietic Stem Cell Mobilization. *Stem Cell Mobilization. *Mobilization, Stem Cell ... "Hematopoietic Stem Cell Mobilization" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, ... Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. ...
Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for ... while its success primarily relies on mobilization to obtain sufficient hematopoietic stem/progenitor cells (HPC). Although the ... Autologous stem cell transplantation (ASCT) is the only curable therapy for multiple myeloma (MM), ... Mobilization with PEG yielded significantly higher median number of collected CD34+ cells than FIL (5.56 vs. 4.82 × 106/kg; P ...
Mesenchymal stem cells regulate the hematopoietic stem cell mobilization through the endocannabinoids ... Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, İtalya, 18 - 21 Ekim 2016, cilt.27 ...
Fingerprint Dive into the research topics of The whys and hows of hematopoietic progenitor and stem cell mobilization. ... The whys and hows of hematopoietic progenitor and stem cell mobilization. A. Kessinger, J. G. Sharp ...
Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document * ... Rights & permissionsfor article Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection ... Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry *A ... Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial *L Rosiñol ...
keywords = "Autologous stem cell transplantation, Myeloma, Plerixafor, Stem cell mobilization",. author = "Basak, {Grzegorz W ... they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell ... they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell ... they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell ...
Viagra enables rapid and efficient hematopoietic stem cell mobilization in mice The combination of two clinically approved ... 3D-printed cell traps help researchers remove the hay to expose cancer cells Finding a handful of cancer cells hiding among ... In a new approach enabled by 3D-printed cell traps, researchers are removing the hay to expose the cancer cells. ... rapidly and efficiently mobilizes blood stem cells from the bone marrow into the bloodstream in mice, researchers report ...
... are widely used for stem cell transplantation and have advantages over traditional bone marrow-derived HSPCs. This review ... Hematopoietic stem and progenitor cells (HSPCs) mobilized from the bone marrow to the peripheral blood by granulocyte colony‐ ... provides an overview of the events that underlie HSPC mobilization and addresses the relevant cellular and molecular components ... hematopoietic stem cells,stem cell mobilization,stem cell niche,G‐CSF,&subject=Immunology,Molecular Biology,Physiology,Review, ...
Procedure: Hematopoietic stem cell transplantation Mobilization. G-CSF- guidelines, 5-10 mcg/kg/day will be started day +5 and ... Experimental: Hematopoietic stem cell transplantation Hematopoietic stem cell transplantation will be performed after ... Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood ... Hematopoietic Stem Cell Transplant in Devics Disease. The safety and scientific validity of this study is the responsibility ...
The short-term goals of this protocol is to demonstrate that subjects with new-onset T1DM undergoing autologous hematopoietic ... Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus Next ... Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus ... stem cell mobilization and ...
Interacting factors such as stromal derived factor-1/CXCR4, very late antigen-4/vascular cell adhesion molecule-1, Lymphocyte ... which give rise to different blood cell types are present within the bone marrow microenvironment, especially in flat bones ... Advances in Hematopoietic Stem Cell Mobilization and Peripheral Blood Stem Cell Transplantation ... Advances in Hematopoietic Stem Cell Mobilization and Peripheral Blood Stem Cell Transplantation. IJML. 2016; 3 (1) :1-12. URL: ...
  • EMH activation requires hematopoietic stem cell (HSC) proliferation and mobilization, processes that depend upon estrogen receptor α (ERα) in HSCs. (jci.org)
  • Although Notch signaling is not essential for homeostasis of adult hematopoietic stem cells (HSCs), Notch-ligand adhesive interaction maintains HSC quiescence and niche retention. (haematologica.org)
  • These findings identify MuPAR and plasmin as regulators of the proliferation, marrow pool size, homing, engraftment, and mobilization of HSPCs and possibly also of HSCs. (jci.org)
  • Quiescent hematopoietic stem cells (HSCs) reside in the bone marrow (BM) near the endosteum, in specific microenvironments called endosteal niches [ 1 - 3 ]. (hindawi.com)
  • The resulting alteration in the CXCL12 gradient enables hematopoietic stem cells (HSCs) to egress from the bone marrow ( 5 , 8 ). (sciencemag.org)
  • Hematopoietic stem cells (HSCs) mostly reside in the BM, where they undergo proliferation and multi-lineage differentiation, giving rise to mature leukocytes and erythrocytes, which are released in turn to the blood in order to carry out their function ( Orkin and Zon, 2008 ). (stembook.org)
  • Since HSCs are strongly retained in specialized niches in the BM ( Adams and Scadden, 2006 - Lo Celso and Scadden, 2011 ) (also reviewed in this StemBook), the mere mechanistic concept of cell egress is deliberate detachment of HSCs and their active trafficking from the BM to the blood stream in order to accommodate blood cell replenishment on demand. (stembook.org)
  • The present study (ClinicalTrials.gov Identifier: NCT02221492) was conducted to assess the efficacy and safety of plerixafor for the mobilization and collection of haematopoietic stem cells (HSCs) for autologous transplantation in Japanese non-Hodgkin lymphoma (NHL) patients. (springer.com)
  • We found that plerixafor was well tolerated and effective for the mobilization and collection of peripheral HSCs for autologous transplantation in Japanese NHL patients. (springer.com)
  • The vast majority of hematopoietic stem cells (HSCs) reside in specialized niches within the bone marrow during steady state, maintaining lifelong blood cell production. (biomedcentral.com)
  • Hematopoietic stem cells (HSCs) are able to migrate through the blood stream and engraft bone marrow (BM) niches. (rupress.org)
  • Here we determine the degree of hematopoietic migration at a clonal level by transplanting individual young and aged mouse HSCs labeled with barcoded viral vector, followed by assessing the skeletal distribution of hundreds of HSC clones. (rupress.org)
  • Continuous generation and regeneration of all blood and immune cells over the lifespan of an organism is ensured by a limited number of hematopoietic stem cells (HSCs). (rupress.org)
  • The migrating ability of HSCs is routinely used in clinical transplantation and gene therapy protocols, which are applied in the treatment of an increasing number of hematopoietic and nonhematopoietic diseases. (rupress.org)
  • The mobilizing effect of granulocyte colony-stimulating factor is not completely understood, but recent studies suggest that its capacity to mobilize HSCs, at least in part, is a consequence of alterations to the hematopoietic niche. (hoggattlab.com)
  • Activated platelets accumulate at the site of a vascular injury, where they support the escape of the hematopoeitic stem cells (HSCs) from flow and provide a pro-angiogenic niche (fertile-soil). (einthovenlaboratory.com)
  • Upon immobilization of the HSCs, they become subject to shear stress, which leads to the expression of the receptor for vascular endothelial growth factor receptor (VEGFR), representing a marker of the differentiation/ maturation towards an endothelial cell phenotype. (einthovenlaboratory.com)
  • Mobilization of hematopoietic stem cells (HSCs) from the bone marrow (BM) into blood circulation can be elicited by the cytokine granulocyte-colony stimulating factor (GCSF). (yu.edu)
  • In this study, we identify that muscarinic receptor type-1 (Chrm1) signaling within the central nervous system (CNS) promotes G-CSF mobilization of HSCs. (yu.edu)
  • Microarray analysis of Chrm1-/- HSCs indicated that glucocorticoids contribute to the steady state organization of 3D actin structures and indeed, hematopoietic cells isolated from Chrm1-/- and Nr3c1Delta/Delta mice were observed to exhibit reduced polymerized actin by phalloidin staining compared to wild-type cells. (yu.edu)
  • This suggests that steady state levels of glucocorticoids in the BM microenvironment prime HSCs for GCSF elicited mobilization through the organization of 3D actin networks. (yu.edu)
  • The complex interaction between hematopoietic stem cells (HSCs) and their microenvironment in the human bone marrow ensures a life-long blood production by balancing stem cell maintenance and differentiation. (cambridge.org)
  • Rapid and synergistic mobilization of HSPCs along with an enhanced recruitment of true HSCs was achieved when a CXCR2 agonist was coadministered in conjunction with a VLA4 inhibitor. (jci.org)
  • Hematopoietic stem cells (HSCs) reside in specialized bone marrow (BM) niches regulated by the sympathetic nervous system (SNS). (nih.gov)
  • Using MO and MΦ conditional depletion models, we found that reductions in BM mononuclear phagocytes led to reduced BM CXCL12 levels, the selective down-regulation of HSC retention genes in Nestin(+) niche cells , and egress of HSCs/progenitors to the bloodstream. (nih.gov)
  • These results highlight two antagonistic, tightly balanced pathways that regulate maintenance of HSCs/progenitors in the niche during homeostasis, in which MΦ cross talk with the Nestin(+) niche cell promotes retention , and in contrast, SNS signals enhance egress. (nih.gov)
  • Thus, strategies that target BM MΦ hold the potential to augment stem cell yields in patients that mobilize HSCs/progenitors poorly. (nih.gov)
  • The complex microenvironment that surrounds hematopoietic stem cells (HSCs) in the bone marrow niche involves different coordinated signaling pathways. (springer.com)
  • Dexter observed that mesenchymal stromal cells could maintain early HSCs ex vivo, and both Lord and Gong showed that these cells localized to the endosteal margins in long bones. (wikipedia.org)
  • SCF may serve as guidance cues that direct hematopoietic stem cells (HSCs) to their stem cell niche (the microenvironment in which a stem cell resides), and it plays an important role in HSC maintenance. (wikipedia.org)
  • SCF plays a role in the regulation of HSCs in the stem cell niche in the bone marrow. (wikipedia.org)
  • The stromal cells that surround HSCs are a component of the stem cell niche, and they release a number of ligands, including SCF. (wikipedia.org)
  • In the bone marrow, HSCs and hematopoietic progenitor cells are adjacent to stromal cells, such as fibroblasts and osteoblasts (Figure 2). (wikipedia.org)
  • These HSCs remain in the niche by adhering to ECM proteins and to the stromal cells themselves. (wikipedia.org)
  • In fact, fetal HSCs in cell culture are 6 times more sensitive to SCF than adult HSCs based on the concentration that allows maximum survival. (wikipedia.org)
  • Adult hematopoietic stem cells (HSCs) exist in a relatively quiescent state in the bone marrow (BM) microenvironment to fulfill long-term self-renewal and multilineage differentiation functions, an event that is tightly regulated by extrinsic and intrinsic cues. (pnas.org)
  • In a conditional-knockout mouse model, we show that Cdc42 −/− HSCs enter the active cell cycle, resulting in significantly increased number and frequency of the stem/progenitor cells in the BM. (pnas.org)
  • Adult hematopoietic stem cells (HSCs) exist in a relatively quiescent state in the bone marrow (BM) microenvironment to execute long-term self-renewal and multilineage differentiation functions ( 1 - 3 ). (pnas.org)
  • A number of genes that encode cell cycle or transcriptional regulators, including p21 Cip1 , p27 Kip1 , β-catenin/axin, cyclin D1, and c-Myc ( 4 , 5 ), have been shown to regulate the intrinsic programs of HSCs in this process. (pnas.org)
  • Despite of the identification of these molecular factors in HSCs and in BM that may collectively contribute to the maintenance of quiescence ( 7 ), the mechanism coordinating HSC cell cycle regulation and niche interaction remains unclear. (pnas.org)
  • Although its function has been extensively studied in various cell systems by expression of dominant negative or constitutively active mutants ( 12 ), the physiological roles of Cdc42 in most primary cell lineages, particularly in HSCs, remain unclear. (pnas.org)
  • Our results unveil a role of Cdc42 in maintaining HSC quiescence and in retaining HSCs in the correct location in the BM niche by regulating the expression of a number of key cell cycle regulators (including c-Myc and p21 Cip1 ) and cell adhesion molecules (such as β1-integrin and N-cadherin) and the actin structure. (pnas.org)
  • 10 ) succeeded in exploiting hematopoietic stem cells (HSCs) to treat new-onset T1D and achieved encouraging results, paving the way for another three trials, which were initiated worldwide ( 11 , 12 ). (diabetesjournals.org)
  • The rationale for the use of HSCs in treating subjects with T1D is based upon the immunoregulatory properties of HSCs, which may help to rescue peripheral tolerance toward pancreatic β-cells by reshaping the immune response ( 13 , 14 ). (diabetesjournals.org)
  • Mozobil ® 20 mg/mL solution for injection containing plerixafor as active pharmaceutical ingredientis indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) [ 1 ]. (degruyter.com)
  • Hematopoietic progenitor cells (HPCs) or hematopoietic stem cells (HSCs) are cells present in blood and bone marrow. (aabb.org)
  • Magenta is developing MGTA-145 in combination with plerixafor utilizing complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation. (businesswire.com)
  • Stem cell maintenance in a haltered cell-cycle state (i.e., quiescence) has been proposed as a fundamental property of HSCs. (nii.ac.jp)
  • Maintenance of quiescence protects HSCs from functional exhaustion and naturally producing extrinsic cellular insults to enable lifelong hematopoietic cell production. (nii.ac.jp)
  • In HIF-1α deficiency, HSCs became metabolically aerobic, lost cell cycle quiescence, and finally exhausted. (nii.ac.jp)
  • The combination of two clinically approved drugs--Viagra and Plerixafor--rapidly and efficiently mobilizes blood stem cells from the bone marrow into the bloodstream in mice, researchers report October 10th in the journal Stem Cell Reports. (news-medical.net)
  • Another drug that mobilizes hematopoietic stem cells is Plerixafor, but it is not very effective as a single agent. (news-medical.net)
  • By contrast, mice treated with Plerixafor alone showed a nearly 3-fold increase in hematopoietic cells compared to control mice, consistent with findings from previous studies. (news-medical.net)
  • Mice treated with a single oral dose of Viagra combined with an injection of Plerixafor had approximately 2,500 more hematopoietic stem cells in the bloodstream within 2 hours, representing a 7.5-fold increase compared to control mice. (news-medical.net)
  • Three days of oral Viagra combined with a single injection of Plerixafor was slightly more effective, resulting in approximately 2,800 more hematopoietic stem cells--an 8.4-fold increase compared to control mice. (news-medical.net)
  • The researchers next harvested hematopoietic stem cells from the blood or bone marrow of donor mice treated with either Plerixafor alone or a combination of Viagra and Plerixafor and then transplanted these cells into recipient mice. (news-medical.net)
  • These experiments revealed that the combination of Viagra and Plerixafor outperforms Plerixafor alone, resulting in the long-term engraftment of functional, self-renewing, multipotent hematopoietic stem cells, suggesting that this approach may be suitable for hematopoietic stem cell transplantation in patients. (news-medical.net)
  • As G-CSF can cause life-threatening SCD complications and is contraindicated, plerixafor, a CXCR4 receptor antagonist, may accomplish HSC mobilization without the neutrophil or endothelial activation that elicit vaso-occlusion. (confex.com)
  • We modified the protocol for the HGB-206 phase 1 study of LentiGlobin GT in severe SCD (NCT02140554) to assess HSC mobilization with plerixafor alone, followed by apheresis and transduction of mobilized cells. (confex.com)
  • To date, 3 patients have undergone plerixafor mobilization. (confex.com)
  • Patients had a transient 1.5- to 3-fold increase in peak white blood cell and absolute neutrophil levels after plerixafor. (confex.com)
  • 15 ×103 cells/uL on day 4 of filgrastim or tbo-filgrastim mobilization for allogeneic transplantation and the use of plerixafor in both patient populations. (mdedge.com)
  • Kessans MR, Gatesman ML, Kockler DR. Plerixafor: a peripheral blood stem cell mobilizer. (springer.com)
  • Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. (springer.com)
  • Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. (uchicago.edu)
  • Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. (uchicago.edu)
  • Villa CH, Shore T, Van Besien K, Cushing M. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. (uchicago.edu)
  • We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. (elsevier.com)
  • Our data suggest that stem cell mobilization with plerixafor and G-CSF might overcome the negative effect of prognostic factors for poor stem cell mobilization in patients with MM who have undergone autoSCT previously. (elsevier.com)
  • Objectives: The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. (uantwerpen.be)
  • Optimal collection (defined as a total yield >4 x 10(6) CD34+ cells/kg) was obtained for 43% of the study population (31% in lymphoma patients, compared to 61% in patients with MM). The use of plerixafor was in line with the SmPC and the Belgian reimbursement criteria for all patients. (uantwerpen.be)
  • However, a uniform PB CD34 + cell count that predicts mobilization failure has not been defined, resulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of when to use the novel stem cell mobilization agent plerixafor. (elsevier.com)
  • Regardless of the PB CD34 + cell count, the total yield of CD34 + cells from apheresis was significantly higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group collected the minimum (≥2 × 10 6 cells/kg) and optimum (≥6 × 10 6 cells/kg) stem cell yields on each day of apheresis. (elsevier.com)
  • As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for significantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. (elsevier.com)
  • For all CD34 + cell count groups, the proportion of patients proceeding to transplantation and the median time to platelet and neutrophil engraftment were similar in the plerixafor and placebo groups. (elsevier.com)
  • Our findings demonstrate that in patients with multiple myeloma who might be predicted to fail mobilization based on low PB CD34 + cell count, the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater proportion of patients compared with G-CSF alone. (elsevier.com)
  • In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34 + cell counts (≥20 cells/μL) compared with placebo plus G-CSF. (elsevier.com)
  • The CXCR4 inhibitor plerixafor is a more rapid mobilizer, yet not potent enough when used as a single agent, thus emphasizing the need for faster acting agents with more predictable mobilization responses and fewer side effects. (jci.org)
  • Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. (semanticscholar.org)
  • A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the 'on-demand' scheme of administration at French autologous hematopoietic stem cell transplant programs. (semanticscholar.org)
  • Data from this preclinical study demonstrate the potential of MGTA-145 plus plerixafor to serve as an efficient, single-dose mobilization regimen for in vivo HSC gene therapy where stem cells could be gene corrected or edited without having to remove them from the body. (businesswire.com)
  • Data from this Phase 1 clinical trial with healthy volunteers further underscore the potential utility of MGTA-145 plus plerixafor as an effective, single-day mobilization and collection regimen for autologous and allogeneic HSC transplant. (businesswire.com)
  • The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: a randomized phase II study. (clinicaltrialsregister.eu)
  • abstract = "Previous studies from our laboratory indicate that functional, mature neutrophils are essential for interleukin-8 (IL-8)-induced stem cell mobilization. (rug.nl)
  • Concomitantly, IL-33 induced hematopoietic stem and progenitor cell (HSPC) mobilization and extramedullary hematopoiesis. (jimmunol.org)
  • HSPC mobilization was mediated mainly through increased levels of CCL7 produced by vascular endothelial cells in response to IL-33. (jimmunol.org)
  • Consistently, inhibitor of CCR2 markedly reduced IL-33-mediated HSPC mobilization in vivo and migration of HSPCs in response to CCL7 in vitro. (jimmunol.org)
  • The mechanisms of BM hematopoietic stem/progenitor cell (HSPC) adhesion, engraftment, and mobilization remain incompletely identified. (jci.org)
  • The activity of osteoclasts seems required for the mobilization of hematopoietic stem and progenitor cells (HSPC) from the bone marrow to the periphery. (hindawi.com)
  • In agreement with osteoclast-dependent HSPC mobilization, administration of calcitonin led to milder splenomegaly, reduced numbers of HSPC in the spleen, and their retention in the bone marrow. (hindawi.com)
  • Recent studies involve bone resorbing osteoclasts in the homeostasis and mobilization of HSC and hematopoietic progenitor cells (HSPC) in conditions of stress, although this function remains controversial [ 8 - 11 ]. (hindawi.com)
  • Indeed, stimulation of osteoclasts activity by Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) increases HSPC mobilization through secretion of cathepsin K, which cleaves c-Kit-ligand and Stromal Cell-Derived Factor 1 (SDF-1), required for maintenance of endosteal niches. (hindawi.com)
  • Furthermore, the osteoclast inhibiting hormone calcitonin was reported to decrease HSPC mobilization in response to LPS injection [ 11 ]. (hindawi.com)
  • However, contradictory evidences demonstrate that inhibition of osteoclast activity by bisphosphonate does not impair HSPC mobilization in response to Granulocyte-Colony Stimulating Factor (G-CSF) treatment [ 1 , 10 ], suggesting that osteoclasts may only intervene in certain types of hematopoietic stresses. (hindawi.com)
  • Mobilization of HSPC is triggered by viral, bacterial, and Plasmodium infection [ 12 - 16 ], as well as by phenylhydrazine- (PHZ-) induced anemia in mice [ 17 - 19 ], but the contribution of osteoclasts in these responses has not been yet characterized. (hindawi.com)
  • However, some patients fail to achieve sufficient HSPC mobilization. (sciencemag.org)
  • Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to down-modulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). (sciencemag.org)
  • The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. (sciencemag.org)
  • These data suggest that there are diabetes-induced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients. (sciencemag.org)
  • G-CSF is the mobilizing agent most widely used in clinics and elicits HSPC mobilization through several putative mechanisms ( 5 ). (sciencemag.org)
  • HSPC mobilization is induced clinically or experimentally in animal models by a wide variety of agents, such as cytokines (e.g. (stembook.org)
  • Thus, deciphering mechanisms that regulate HSPC motility can be utilized for the development of improved mobilization regimens. (stembook.org)
  • Differentiating myeloid cells, bone remodeling by osteoblasts and osteoclasts, stimuli of the innate immunity as well as of the nervous system, including signals emanating the circadian clock, highly regulate various aspects of HSPC function, including egress, recruitment and mobilization. (stembook.org)
  • This review provides an overview of the events that underlie HSPC mobilization and addresses the relevant cellular and molecular components of the bone marrow niche from which the HPSCs are mobilized from. (researchpad.co)
  • 5 5 This higher HSPC yield obtained through the mobilization of HSPCs has allowed for the development of novel HSPC transplantation modalities, such as unrelated transplantation, haploidentical transplantation, and nonmyeloablative transplantation. (researchpad.co)
  • 5 5 Moreover, diabetes mellitus also correlates with a lower CD34 + yield after cytokine‐induced HSPC mobilization. (researchpad.co)
  • In G-CSFinduced HSPC mobilization, the bone marrow osteoblasts retraction causes reduction of Ang1, and the reduction of Ang1 may contribute to HSPC mobilization. (bvsalud.org)
  • Mobilized peripheral blood has become the primary source of hematopoietic stem and progenitor cells (HSPCs) for stem cell transplantation, with a 5-day course of granulocyte colony-stimulating factor (G-CSF) as the most common regimen used for HSPC mobilization. (jci.org)
  • Given the rapid kinetics and potency of HSPC mobilization achieved by the VLA4 inhibitor and CXCR2 agonist combination in mice compared with currently approved HSPC mobilization methods, the combination represents an exciting potential strategy for clinical development in the future. (jci.org)
  • Using Notch receptor blocking antibodies, we report that Notch2 blockade, but not Notch1 blockade, sensitizes hematopoietic stem cells and progenitors (HSPCs) to mobilization stimuli and leads to enhanced egress from marrow to the periphery. (haematologica.org)
  • In addition, we found that Notch2-blocked or Notch2-deficient marrow HSPCs show an increased homing to the marrow, while mobilized Notch2-blocked, but not Notch2-deficient stem cells and progenitors, displayed a competitive repopulating advantage and enhanced hematopoietic reconstitution. (haematologica.org)
  • In addition to Th2 cells, IL-33 has been shown to act on macrophages ( 9 ), dendritic cells ( 10 ), mast cells ( 11 ), basophils ( 12 ), eosinophils ( 13 ), natural helper cells ( 14 ), nuocytes ( 15 ), and multipotent progenitors ( 16 ). (jimmunol.org)
  • Tissues characterized by constant turnover contain post-mitotic, terminally differentiated cells originating from highly proliferative progenitors, which in turn derive from a relatively small population of st. (biomedcentral.com)
  • SDF-1-responsive cell types include monocytes and macrophages, B and T lymphocytes, platelets and megakaryocytes, and CD34 + cells, including both hematopoietic progenitors and stem cells. (elsevier.com)
  • VEGF elevation was associated with rapid mobilization of hematopoietic stem and progenitor cells and a population of Flk-1-positive endothelial progenitors. (elsevier.com)
  • In contrast angiopoietin induced a delayed mobilization of endothelial and hematopoietic progenitors. (elsevier.com)
  • This event requires a special environment, termed the hematopoietic stem cell niche, which provides the protection and signals necessary to carry out the differentiation of cells from HSC progenitors. (wikipedia.org)
  • SCF also increases the survival of various hematopoietic progenitor cells, such as megakaryocyte progenitors, in vitro. (wikipedia.org)
  • Patients with DM had significantly impaired mobilization of CD34 + , CD133 + , and CD34 + CD133 + hematopoietic stem cells and CD133 + KDR + endothelial progenitors, independently of potential confounders. (diabetesjournals.org)
  • Furthermore, because the BM harbors a variety of regenerative nonhematopoietic progenitors, including endothelial progenitor cells (EPCs), BM dysfunction may contribute to the onset of chronic DM complications ( 12 ). (diabetesjournals.org)
  • Single adult human CD34(+)/Lin‐/CD38(-) progenitors give rise to natural killer cells, B‐lineage cells, dendritic cells, and myeloid cells. (currentprotocols.com)
  • G-CSF is also a potent inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the bloodstream, although it has been shown that it does not directly affect the hematopoietic progenitors that are mobilized. (wikipedia.org)
  • Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. (springer.com)
  • Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. (bvsalud.org)
  • Autologous stem cell transplantation (ASCT) is the only curable therapy for multiple myeloma (MM), while its success primarily relies on mobilization to obtain sufficient hematopoietic stem / progenitor cells (HPC). (bvsalud.org)
  • A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. (elsevier.com)
  • SUMMIT, N.J.--( BUSINESS WIRE )--Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). (businesswire.com)
  • Autologous stem cell transplant after induction therapy is part of the continuum of care for transplant-eligible multiple myeloma patients. (businesswire.com)
  • Preapheresis peripheral blood (PB) CD34 + cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success of HSC collection in patients with multiple myeloma. (elsevier.com)
  • The course of anxiety, depression and unmet needs in survivors of Diffuse Large B Cell Lymphoma and Multiple Myeloma in the early survivorship period. (archive.org)
  • A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. (osu.edu)
  • Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells. (osu.edu)
  • Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34 + HSPCs. (sciencemag.org)
  • The US Food and Drug Administration (FDA) approved the biologic medication filgrastim to mobilize hematopoietic progenitor cells (HPCs) into the peripheral blood for collection by leukapheresis for hematopoietic stem cell transplant (HSCT). (mdedge.com)
  • Patients were identified from the bone marrow transplant clinic and included in data collection if they received filgrastim or tbo-filgrastim for HPC mobilization between September 1, 2012 and September 1, 2018. (mdedge.com)
  • Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. (uchicago.edu)
  • Lenalidomide maintenance therapy, which has been shown to increase progression-free survival following autologous stem cell transplant in clinical trials can be considered a standard of care for these patients. (businesswire.com)
  • Based on recent outcomes of stem cell transplant trials and reports in autoimmune diseases including MS, and based on the mechanisms of NMO, we anticipate that stem cell transplantation may provide lasting disease stability for NMO patients. (clinicaltrials.gov)
  • This process, termed mobilization, has become the primary means to acquire a stem cell graft for hematopoietic transplant at most transplant centers. (hoggattlab.com)
  • Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. (bioportfolio.com)
  • This phase I/II trial studies the side effects and best dose of bortezomib when given together with melphalan, and total-body irradiation before stem cell transplant and to see how well it. (bioportfolio.com)
  • This type of treatment is called a bone marrow or stem cell transplant. (aabb.org)
  • Here is a list of diseases for which stem cell transplant may be an option. (aabb.org)
  • CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021. (businesswire.com)
  • Magenta continues to generate encouraging data across our pipeline, furthering our commitment to patients to expand eligibility and improve the clinical outcomes with stem cell transplant," said John Davis Jr., M.D., M.P.H., M.S., Magenta's Head of Research & Development and Chief Medical Officer. (businesswire.com)
  • Magenta's targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to transplant or gene therapy, and to reduce or potentially eliminate the need for high dose or high intensity chemotherapy-based treatments. (businesswire.com)
  • These programs focus on developing targeted products that remove specific cell types, with an approach that is tailored to the patient's disease and transplant requirements. (businesswire.com)
  • MGTA-117, Magenta's most advanced conditioning program, is a CD117-targeted ADC designed to precisely deplete hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant, and to support long-term engraftment and improved disease outcomes in patients. (businesswire.com)
  • Recently biosimilars of granulocyte-colony-stimulating factor (G-CSF) became available for prophylaxis and treatment of postchemotherapy neutropenia and for mobilization of peripheral blood CD34+ cells for either autologous or allogeneic hematopoietic stem cell transplant. (wiley.com)
  • High-dose chemotherapy with autologous hematopoietic stem cell transplant is still an essential step of the standard care for selected types of cancer in children at high risk of relapse with conventional chemotherapy. (wiley.com)
  • 1 ] The use of mobilized peripheral blood stem cells (PBSCs) is preferred in the autologous transplant setting because of the easier collection procedure and the faster hematologic recovery. (wiley.com)
  • Hematopoietic progenitor cells (HPCs) normally reside in the bone marrow (BM) but can be mobilized into the peripheral blood (PB) after treatment with GCSF or chemotherapy. (jci.org)
  • Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. (springer.com)
  • A total of 91 patients who received either a single dose of PEG (6 or 12 mg, n = 42) or multiple dosing of 10 µg/kg/day FIL (n = 49) after chemotherapy for HPC mobilization were included. (bvsalud.org)
  • Our results support a notion that PEG (especially 12 mg) combined with chemotherapy is a cost -effective and convenient regimen of mobilization, which might improve the outcome of ASCT in MM. (bvsalud.org)
  • A compound effective in killing chemotherapy-resistant glioblastoma-initiating cells has been identified, raising hopes of producing drugs capable of eradicating refractory tumors with low toxicity. (news-medical.net)
  • 5 5 Several factors are associated with mobilization failure, such as advanced age, a diagnosis of lymphoma, previous radiotherapy or extensive chemotherapy, treatment with immunomodulatory drugs or purine analogs, previous mobilization failure, and low preapheresis circulating peripheral blood CD34 + cells. (researchpad.co)
  • The purpose of the intense chemotherapy is to destroy the cells in patient's immune system, which may be causing his/her disease. (clinicaltrials.gov)
  • To assess high-dose carboplatin chemotherapy with or without paclitaxel with filgrastim mobilized peripheral blood progenitor cell (PBPC) support in a phase I/II study, a total of 21 patients with mostly chemonaive disease received four cycles of high-dose chemotherapy. (nih.gov)
  • Available mobilization procedures use either cytokines alone, predominantly granulocyte colony-stimulating factor, or cytokines in combination with chemotherapy. (unibz.it)
  • Long-term thyroid disorders in pediatric survivors of hematopoietic stem cell transplantation after chemotherapy-only conditioning. (bioportfolio.com)
  • The study evaluates the effect of inactivation of the immune system with chemotherapy and immunotherapy and infusion of bone marrow stem cells in early onset type 1 diabetes mellitus. (bioportfolio.com)
  • In a retrospective case series of patients undergoing BM autotransplantation, DM was statistically associated with poor mobilization in response to chemotherapy plus human recombinant granulocyte colony-stimulating factor (hrG-CSF) ( 7 ). (diabetesjournals.org)
  • Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. (bloodjournal.org)
  • 1 Patients with disease that is sensitive to salvage chemotherapy typically proceed to high-dose chemotherapy and autologous stem cell transplantation (ASCT) with curative intent. (bloodjournal.org)
  • Dickinson, M. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. (archive.org)
  • Intended to support conversations between cancer patients undergoing strong chemotherapy and their healthcare team about potential risk for infection due to a low white blood cell count, Neulasta Onpro NARRATIVES shares personal cancer stories as well as educational materials. (prnewswire.com)
  • Patients donating autologous PBPCs also may receive chemotherapy as part of mobilization. (aabb.org)
  • Data were collected on all children undergoing first peripheral blood stem cell (PBSC) mobilization after stimulation with biosimilar G-CSF and chemotherapy. (wiley.com)
  • The answer to these questions will benefit patients receiving extensive chemotherapy who require hematopoietic support or who could benefit from curative hematopoietic stem cell transplantation. (iu.edu)
  • Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells ( neutropenia ), making patients susceptible to infections and sepsis . (wikipedia.org)
  • Fulphila has been approved to reduce the duration of febrile neutropenia (fever or other signs of infection with a low count of neutrophils, a type of white blood cells) in patients treated with chemotherapy in certain types of cancer. (biospace.com)
  • The successful transplantation of hematopoietic stem/progenitor cells (HSPCs) is based on their ability to home to the BM niche and on their engraftment capacity. (hindawi.com)
  • The use of mobilized peripheral blood is now the method of choice in autologous transplantation for various reasons, including an elevated production of immature cells, and, in comparison to the utilization of BM, the shorter time period required for a satisfactory repopulation, the more rapid engraftment, fewer technical difficulties, lower risk, and considerably less pain [ 6 ]. (hindawi.com)
  • These findings suggest that blocking Notch2 combined with the current clinical regimen may further enhance HPC mobilization and improve engraftment during HCT. (haematologica.org)
  • Cell-autonomous loss of the gene encoding MuPAR also impaired long-term engraftment and multilineage repopulation in primary and secondary recipient mice. (jci.org)
  • Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, Cushing MM, Singh AD, van Besien K. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. (uchicago.edu)
  • However, to improve engraftment and overcome rejection in haplotype‐mismatched transplantations, doses exceeding a threshold of 10×10 6 CD34 + cells/kg of body weight are needed. (researchpad.co)
  • Pelus, LM & Fukuda, S 2006, ' Peripheral blood stem cell mobilization: The CXCR2 ligand GROβ rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties ', Experimental Hematology , vol. 34, no. 8, pp. 1010-1020. (elsevier.com)
  • Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. (semanticscholar.org)
  • AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. (semanticscholar.org)
  • Previously, in a gain-of-Cdc42 activity, Cdc42GAP −/− mouse model, we have found that constitutively increased Cdc42-GTP species cause increased hematopoietic progenitor apoptosis, disorganized actin structure, and defective engraftment without affecting the cell cycle status ( 13 ). (pnas.org)
  • Sustained engraftment of mice transplanted with IL‐1‐primed blood‐derived stem cells. (currentprotocols.com)
  • 7 The use of blood stem cells is associated with faster recovery of neutrophils and platelets after transplantation (engraftment) than is the case with bone marrow stem cells. (cmaj.ca)
  • Among other effects, G-CSF increases activity of the SNS in the bone marrow microenvironment, where activation of β-adrenergic receptors in stromal cells inhibits synthesis of the chemokine CXCL12 ( 6 , 7 ). (sciencemag.org)
  • This review aims at presenting up to-date results concerning the dynamic interplay between the BM microenvironment and the HSPCs, focusing on molecular mechanisms that lead eventually to mobilization of HSPCs from the BM into the circulation. (stembook.org)
  • Hematopoietic stem/progenitor cells (HSPCs) which give rise to different blood cell types are present within the bone marrow microenvironment, especially in flat bones such as skull, vertebrae, pelvis and chest. (ac.ir)
  • Interacting factors such as stromal derived factor-1/CXCR4, very late antigen-4/vascular cell adhesion molecule-1, Lymphocyte function-associated antigen-1/ intercellular adhesion molecule -1 retain the cells in the microenvironment. (ac.ir)
  • These studies and others supported the idea that bone cells create the HSC niche, and all the research that elucidated this specialized hematopoietic microenvironment stemmed from these landmark studies. (wikipedia.org)
  • Diabetes compromises the bone marrow (BM) microenvironment and reduces the number of circulating CD34 + cells. (diabetesjournals.org)
  • HSC quiescence is regulated through a complex network of cell intrinsic regulations along with extrinsic influences from the microenvironment. (nii.ac.jp)
  • To study a possible role of neutrophils in granulocyte colony-stimulating factor (G-CSF) induced hematopoietic mobilization, we assessed the number of circulating CD34(+) cells in healthy allogeneic stem cell donors on days 3, 4, and 5 of mobilization for comparison with the number of peripheral blood neutrophils and the plasma levels of IL-8, Flt3 ligand (FL), matrix metalloproteinase-9 (MMP-9), and human neutrophil elastase (HNE). (rug.nl)
  • Storch E, Mark T, Avecilla S, Pagan C, Rhodes J, Shore T, van Besien K, Cushing M. A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. (uchicago.edu)
  • 3 3 Patients transplanted with mobilized HSPCs generally receive a higher median number of HSPCs (expressed as CD34 + cell dose) and are more likely to maintain their graft in comparison with patients receiving BM‐derived allografts. (researchpad.co)
  • 4 4 It has been established that a minimum number of 2.0 × 10 6 CD34 + cells/kg of body weight is required for autologous transplantation. (researchpad.co)
  • For myeloablative and nonmyeloablative allogeneic transplantation, a minimum threshold of 3.0 × 10 6 CD34 + cells/kg of body weight is commonly recommended. (researchpad.co)
  • 6 6 Since higher CD34 + cell doses accelerate hematopoietic recovery, the transplantation of high numbers of CD34 + cells is also important for transplantations in elderly patients, who have an increased risk of transplantation‐related morbidity and mortality. (researchpad.co)
  • The hematopoietic graft mobilized by GROβ contains significantly more CD34 neg , Sca-1 + , c-kit + , lineage neg (SKL) cells than the graft mobilized by G-CSF. (elsevier.com)
  • In vitro, mobilized BM plasma exhibited decreased chemotactic effect on CD34(+) cells, compared with steady-state BM plasma. (qxmd.com)
  • MMP-9 enriched supernatant from HT1080 cell-conditioned medium upregulated CXCR4 expression and the migration of BM CD34(+) cells toward SDF-1. (qxmd.com)
  • SDF-1 was a substrate for MMP-9, furthermore, SDF-1 also stimulated MMP-9 proteolytic enzyme activity of BM CD34(+) cells, which facilitate HSPCs migration. (qxmd.com)
  • Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. (qxmd.com)
  • The number of CD34(+), CD38(+) and CD117(+) cells in peripheral blood was analyzed by flow cytometer. (bvsalud.org)
  • The number of circulating CD34(+) cells in Ad(5)-HGF gene treatment group 6 hours after procedure and the number of circulating CD117(+) cells 6 days post procedure were significantly higher in Ad(5)-HGF gene treatment group than those in the control group (0.104 +/- 0.082 vs. 0.022 +/- 0.012, P = 0.021) and (0.058 +/- 0.058 vs. 0.012 +/- 0.009, P = 0.034), respectively. (bvsalud.org)
  • RESULTS In response to hrG-CSF, levels of CD34 + cells and other progenitor cell phenotypes increased in subjects without DM. (diabetesjournals.org)
  • DM was also associated with the inability to upregulate CD26/DPP-4 on CD34 + cells, which is required for the mobilizing effect of granulocyte colony-stimulating factor. (diabetesjournals.org)
  • Moreover, in support of the existence of a BM defect in human DM, we have shown a reduction in BM CD34 + cells, compared with nondiabetic subjects ( 9 ). (diabetesjournals.org)
  • We report that, in patients, cardiovascular DAN was associated with fewer circulating CD34 + cells. (diabetesjournals.org)
  • CD34 + Flk1 + ) mobilization, and vascular recovery after ischemia. (diabetesjournals.org)
  • Diabetes reduces the availability of bone marrow (BM)-derived circulating angiocompetent CD34 + cells, especially in the presence of chronic vascular complications ( 1 , 2 ). (diabetesjournals.org)
  • This is believed to represent a risk factor for adverse outcomes, as a low CD34 + cell count is associated with incident cardiovascular events ( 3 ). (diabetesjournals.org)
  • Starting from the observation that patients with DAN have a marked pauperization of peripheral blood (PB) CD34 + cells, we used several experimental models and conditions to demonstrate that autonomic neuropathy in the BM is causally linked to impaired stem cell mobilization in diabetes, which is associated with defective reperfusion after ischemia. (diabetesjournals.org)
  • A functional comparison of CD34 + CD38‐ cells in cord blood and bone marrow. (currentprotocols.com)
  • Hematopoietic stem cells were monitored by flow cytometry analysis of circulating CD34+ and CD34+CD38- cells, and peripheral cytokines were assessed by electrochemoluminescence throughout the intervention period. (frontiersin.org)
  • We show that transient Notch2 blockade or Notch2-loss in mice lacking Notch2 receptor lead to decreased CXCR4 expression by HSC but increased cell cycling with CXCR4 transcription being directly regulated by the Notch transcriptional protein RBPJ. (haematologica.org)
  • We now report that mobilization of HPCs by GCSF coincides in vivo with the cleavage of the N-terminus of the chemokine receptor CXCR4 on HPCs resident in the BM and mobilized into the PB. (jci.org)
  • This cleavage of CXCR4 on mobilized HPCs results in the loss of chemotaxis in response to the CXCR4 ligand, the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12). (jci.org)
  • Since both SDF-1 and its receptor, CXCR4, are essential for the homing and retention of HPCs in the BM, the proteolytic degradation of SDF-1, together with that of CXCR4, could represent a critical step leading to the mobilization of HPCs into the PB in response to GCSF or CY. (jci.org)
  • The chemokine stromal derived factor-1 (SDF-1, also termed CXCL12) and its major receptor CXCR4 are crucial in mediating both retention and mobilization of HSPCs, and this chapter will emphasize its recently revealed roles in directing steady state egress and rapid mobilization. (stembook.org)
  • Leukocytosis and mobilization of CD34+ Hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. (springer.com)
  • The chemokine stroma-derived factor-1 (SDF-1) is produced within the bone marrow and mediates chemokinesis and chemotaxis on a variety of cell types that express the CXCR4 receptor. (elsevier.com)
  • The marrow homing ability of GROβ-mobilized cells is less dependent on the CXCR4/SDF-1 axis than cells mobilized by G-CSF. (elsevier.com)
  • The role of stromal cell-derived factor and its receptor-CXCR4 in G-CSF-induced hematopoietic stem cell mobilization]. (qxmd.com)
  • G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. (qxmd.com)
  • Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis. (qxmd.com)
  • MΦ depletion also enhanced mobilization induced by a CXCR4 antagonist or granulocyte colony-stimulating factor. (nih.gov)
  • A novel CXCR4 antagonist for hematopoietic stem cell mobilization. (semanticscholar.org)
  • Recent experiments in the Forsberg lab have shown that increasing vascular permeability helps mobilize hematopoietic stem cells from the bone marrow into the bloodstream. (news-medical.net)
  • Chemokines direct the movement of leukocytes, including hematopoietic stem and progenitor cells, and can mobilize hematopoietic cells from marrow to peripheral blood where they can be used for transplantation. (elsevier.com)
  • Intracoronary administration of Ad(5)-HGF could mobilize hematopoietic stem cells into peripheral blood and the consequent role of this observation on myocardial regeneration warrants further detailed studies. (bvsalud.org)
  • Under normal conditions, IL-33 is localized in the nucleus of endothelial and epithelial cells ( 5 ) and has chromatin-binding activity ( 6 ). (jimmunol.org)
  • We have identified a bone marrow-derived, circulating endothelial stem cell characterized by expression of the VEGFR2 (Flk-1/KDR). (elsevier.com)
  • GROβ-mobilized SKL cells demonstrate enhanced adherence to vascular cell adhesion molecule-1 and VCAM pos endothelial cells and home more efficiently to bone marrow in vivo. (elsevier.com)
  • Under a strong positive selection pressure bone marrow derived stem cells may be involved in this process, by making a contribution to both parenchymal restoration and endothelial cell replacement. (unicatt.it)
  • The stem cells establish permanent interactions with distinct cell types such as mesenchymal stromal cells, osteoblasts, osteoclasts or endothelial cells and with secreted regulators such as growth factors, cytokines, chemokines and their receptors. (springer.com)
  • As the embryo requires rapid oxygenation due to its high mitotic activity, these islands are the main source of red blood cell (RBC) production via fusing endothelial cells (ECs) with the developing embryonic circulation. (wikipedia.org)
  • A year later, Choi showed that blast cells derived from embryonic stem (ES) cells displayed common gene expression of both hematopoietic and endothelial precursors. (wikipedia.org)
  • Soluble and transmembrane SCF is produced by fibroblasts and endothelial cells. (wikipedia.org)
  • Since mobilization of BM-derived stem/progenitor cells contributes to angiogenesis and endothelial repair ( 11 , 12 ), such stem cell "mobilopathy" ( 13 ) is expected to promote cardiovascular disease in diabetes. (diabetesjournals.org)
  • A niche is a subgroup of tissue cells and extracellular substrates that can indefinitely harbor one or more stem cells and control their self-renewal and progeny in vivo [ 3 ]. (hindawi.com)
  • The BM niche is strategically placed and organized to support the continuous and balanced production of hematopoietic cells through the strict control of cell survival, self-renewal, and differentiation [ 4 ]. (hindawi.com)
  • Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). (sciencemag.org)
  • Osteolineage niche cells initiate hematopoietic stem cell mobilization. (bloodjournal.org)
  • All these signaling pathways are important for stem cell fates such as self-renewal, proliferation or differentiation, homing and mobilization, as well as for remodeling of the niche. (springer.com)
  • The key regulatory effects of major medullar HSPGs are described, focusing on their roles in the interactions between hematopoietic stem cells and their endosteal niche, and on their ability to interact with Heparin Binding Proteins (HBPs). (springer.com)
  • Finally, according to the relevance of HS moieties effects on this complex medullar niche, we describe recent data that identify HS mimetics or sulfated HS signatures as new glycanic tools and targets, respectively, for hematopoietic and mesenchymal stem cell based therapeutic applications. (springer.com)
  • During this time, the field exploded with studies aimed at determining the components of the "hematopoietic stem cell niche" that made this possible. (wikipedia.org)
  • The sympathetic nervous system (SNS) is prominently involved in BM niche function ( 14 ) and stem cell trafficking is regulated by catecholaminergic neurotransmitters ( 15 , 16 ). (diabetesjournals.org)
  • AML cells shed extracellular vesicles called exosomes that contain molecules that suppress hematopoiesis by reprogramming the stem cell niche. (sciencemag.org)
  • Cell Types Promoting Goosebumps Form a Niche to Regulate Hair Follicle Stem Cells. (amedeo.com)
  • Figure 2: A diagram of a hematopoietic stem cell (HSC) inside its niche. (wikidoc.org)
  • This project will define the roles of EP4 signaling in the hematopoietic niche that regulate normal and stressed hematopoiesis is. (iu.edu)
  • Sex/gender differences in hematopoietic function and the stem cell niche. (iu.edu)
  • Moreover, the effectiveness of this approach rivaled that of a 4-day G-CSF treatment regimen, which increased the number of hematopoietic stem cells by approximately 3,400. (news-medical.net)
  • Hematopoietic stem cell transplantation will be performed after conditioning regimen. (clinicaltrials.gov)
  • Mobilization as a preparative regimen for hematopoietic stem cell transplantation. (washington.edu)
  • Thyroid dysfunction (TD) was usually described in hematopoietic stem cell transplantation (HSCT) recipients who were given total body irradiation (TBI) in the conditioning regimen. (bioportfolio.com)
  • The patients will receive a nonmyeloablative conditioning regimen with cyclophosphamide and fludarabine, and after this, the cells will be injected intravenously. (bioportfolio.com)
  • This combination has the potential to be the preferred mobilization regimen for rapid, reliable, predictable and safe collection of high numbers of functional blood stem cells to improve outcomes across autologous and allogeneic stem cell transplantation, which also includes stem cells necessary for all HSC-based gene therapies. (businesswire.com)
  • In addition, it is not suitable for the very ill, the elderly, or individuals with sickle cell disease. (news-medical.net)
  • Patients with severe sickle cell disease (SCD) may benefit from β-globin gene transfer into autologous hematopoietic stem cells (HSC). (confex.com)
  • HPCs are used in the treatment of many malignant (e.g., leukemia, lymphoma) and non-malignant (e.g., sickle cell disease) diseases to replace or rebuild a patient's hematopoietic system. (aabb.org)
  • Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). (amedeo.com)
  • Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. (amedeo.com)
  • Chronic organ injuries in children with sickle cell disease. (amedeo.com)
  • How to implement endurance exercise training in sickle cell disease. (amedeo.com)
  • Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy. (amedeo.com)
  • The current standard protocol for hematopoietic stem and progenitor cell mobilization involves multi-day injections of granulocyte-colony stimulating factor (G-CSF). (news-medical.net)
  • In previous studies, we showed that granulocyte precursors accumulate in the BM during mobilization induced by either GCSF or cyclophosphamide (CY), leading to the accumulation of active neutrophil proteases in this tissue. (jci.org)
  • Hematopoietic stem and progenitor cells (HSPCs) mobilized from the bone marrow to the peripheral blood by granulocyte colony‐stimulating factor (G‐CSF) are widely used for stem cell transplantation and have advantages over traditional bone marrow-derived HSPCs. (researchpad.co)
  • HSPCs that have been mobilized by granulocyte colony‐stimulating factor (G‐CSF) from the BM to the peripheral blood have largely replaced BM‐derived HSPCs as a source for autologous stem cell transplantation and are currently used in the majority of allogeneic stem cell transplantations. (researchpad.co)
  • Several factors are involved in hematopoietic stem cells (HSC) mobilization such as granulocyte-colony stimulating factor, sphingosine-1-phosphate, hepatocyte growth factor, complement system, plasminogen system and matrix metalloproteinases. (ac.ir)
  • Currently, the preferred method of HSC mobilization for subsequent transplantation is treatment of the donor with granulocyte colony-stimulating factor. (hoggattlab.com)
  • GROβ rapidly mobilizes short- and long-term repopulating cells in mice and/or monkeys and synergistically enhances mobilization responses when combined with the widely used clinical mobilizer, granulocyte colony-stimulating factor (G-CSF). (elsevier.com)
  • The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization]. (qxmd.com)
  • The CMP can then further differentiate into the megakaryocyte-erythroid progenitor cell (MEP), which goes on to make RBCs and platelets, or the granulocyte/macrophage progenitor (GMP), which gives rise to the granulocytes of the innate immune response. (wikipedia.org)
  • Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony‐stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. (currentprotocols.com)
  • Granulocyte-colony stimulating factor ( G-CSF or GCSF ), also known as colony-stimulating factor 3 ( CSF 3 ), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream . (wikipedia.org)
  • To evaluate safety, tolerability and feasibility of long-term treatment with Granulocyte-colony stimulating factor (G-CSF), a well-known hematopoietic stem cell factor, guided by assessment of mobilized bone marrow derived stem cells and cytokines in the serum of patients with amyotrophic lateral sclerosis (ALS). (frontiersin.org)
  • Here we show that treating mice with estradiol to model estradiol increases during pregnancy induced HSC proliferation in the bone marrow but not HSC mobilization. (jci.org)
  • Cyp27a1-deficient mice had significantly reduced 27HC levels, HSC mobilization, and EMH during pregnancy but normal bone marrow hematopoiesis and EMH in response to bleeding or G-CSF treatment. (jci.org)
  • Here, using WT and transgenic mice, we have shown that membrane-anchored plasminogen activator, urokinase receptor (MuPAR) marks a subset of HSPCs and promotes the preservation of the size of this pool of cells in the BM. (jci.org)
  • Knowing that BALB/c mice with acute Plasmodium chabaudi adami malaria have profound alterations in bone remodelling cells, we evaluated the extent to which osteoclasts influence their hematopoietic response to infection. (hindawi.com)
  • Blood stage malaria causes systemic inflammation and acute hemolytic anemia in mice [ 20 ], which are events that trigger stress hematopoiesis to generate phagocytic cells involved in parasite clearance and new erythrocytes to cope with anemia [ 21 - 24 ]. (hindawi.com)
  • Secondary Objective: To determine the number of CD34+ stem/progenitor cells that are mobilized under these conditions, as well as the ability of these cells to be transduced with a recombinant lentivirus vector for beta-globin and engraft immunodeficient mice. (clinicaltrials.gov)
  • Efficacy will be assessed by measuring the total number of CD34+ cells, the ability of these cells to be transduced with a recombinant lentivirus vector for beta-globin, and the ability of these cells to engraft immunodeficient mice. (clinicaltrials.gov)
  • The proportion of Lin-Sca1⁺cKit⁺ (LSK) cells in peripheral blood of C57BL/6 mice before and after G-CSF mobilization was detected by flow cytometry . (bvsalud.org)
  • In mice, stem cells mobilized by GROβ demonstrate a competitive advantage upon long-term repopulation analysis and restore neutrophil and platelet counts significantly faster than cells mobilized by G-CSF. (elsevier.com)
  • In BALB/c mice, HSPCs mobilization was significantly inhibited by anti-SDF-1 antibodies or MMP inhibitor, o-phenanthroline. (qxmd.com)
  • Blockade of Chrm1 in the CNS, but not in the periphery, resulted in reduced HSC mobilization, similar to that observed in Chrm1-/- mice. (yu.edu)
  • Parabiosis of Chrm1 -/- mice with wild-type mice is sufficient to rescue Chrm14 impaired HSC mobilization, suggesting a blood borne factor mediates the relay of central signals. (yu.edu)
  • Our studies identified Chrm1-/- mice to have significant reductions in plasma and BM glucocorticoids, leading us to explore its role in HSC mobilization. (yu.edu)
  • Mice harboring a glucocorticoid receptor (Nr3c1) deficient hematopoietic system also exhibited reductions in HSC mobilization, further confirming a role for glucocorticoid signals in G-CSF-elicited HSC mobilization. (yu.edu)
  • Administration of physiological levels of glucocorticoids to Chrm1-/- mice was sufficient to restore polymerization of actin in steady state hematopoietic cells. (yu.edu)
  • We sought to improve hematopoietic stem cell transplantation by developing a new mobilization strategy in mice through combined targeting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin. (jci.org)
  • B - D ) For transient depletion of blood neutrophils, mice were pretreated with an anti-Gr1 antibody in vivo (200 μg/mouse, i.v.) 36 hours prior to mobilization with tGro-β (2.5 mg/kg, s.c., time point 15 minutes), CWHM-823 (3.0 mg/kg, s.c., time point 60 minutes), or the combined agents (doses same as for separate treatments, time point 30 minutes). (jci.org)
  • The hemangioblast theory, which posits that the RBCs and ECs derive from a common progenitor cell, was developed as researchers observed that receptor knockout mice, such as Flk1-/-, exhibited defective RBC formation and vessel growth. (wikipedia.org)
  • The gene encoding stem cell factor (SCF) is found on the Sl locus in mice and on chromosome 12q22-12q24 in humans. (wikipedia.org)
  • Mice with SCF or c-Kit mutations have severe defects in the production of mast cells, having less than 1% of the normal levels of mast cells. (wikipedia.org)
  • p66Shc knockout (KO) in diabetic mice prevented DAN in the BM, and rescued defective LKS cell and EPC mobilization. (diabetesjournals.org)
  • Mobilization of long‐term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7. (currentprotocols.com)
  • Competitive in vivo proliferation of foetal and adult haematopoietic cells in lethally irradiated mice. (currentprotocols.com)
  • Adult neural stem cell activation in mice is regulated by the day/night cycle and intracellular calcium dynamics. (amedeo.com)
  • In summary, our findings establish a basal defect in eosinophilopoiesis in IL-33- and ST2-deficient mice and a mechanism whereby IL-33 supports EoMs by driving both systemic IL-5 production and the expansion of IL-5Rα-expressing precursor cells. (jimmunol.org)
  • This project will define the regulatory interactions of PGE2, megakaryocytes, bone forming osteoblasts and mesenchymal stem cells in normal young and aged mice at homeostasis and after irradiation. (iu.edu)
  • multiple rounds of BMH may be required to obtain adequate cell doses for autologous gene therapy (GT) protocols. (confex.com)
  • These features are key factors for successful stem cell transplantations that are used in cancer patients and in gene therapy protocols. (rupress.org)
  • Gene transfer involves obtaining blood stem cells from an individual, adding a normal globin gene to the stem cells, and putting the cells back into the individual. (clinicaltrials.gov)
  • Before gene transfer methods can be attempted in individuals with beta thalassemia major, a safe method of obtaining blood stem cells needs to be developed. (clinicaltrials.gov)
  • Researchers in the laboratory will purify the stem cells from the mixture and test methods of putting a normal globin gene into the stem cells. (clinicaltrials.gov)
  • To investigate the effect of intracoronary adenovirus vector encoding hepatocyte growth factor gene (Ad(5)-HGF) on hematopoietic stem cells mobilization in patients with extensive coronary heart disease . (bvsalud.org)
  • An X-chromosome gene regulates hematopoietic stem cell kinetics. (washington.edu)
  • Cdc42 is a ubiquitously expressed member of the Rho GTPase family involved in the regulation of multiple cell functions, including actin polymerization, cell-to-cell or cell-to-extracellular matrix adhesion, and gene transcription ( 11 ). (pnas.org)
  • To further define the role of Cdc42 in HSC regulation, in this study, we present a conditional-knockout mouse model in which the cdc42 gene is inducibly deleted in hematopoietic cells. (pnas.org)
  • An Engineered CRISPR-Cas9 Mouse Line for Simultaneous Readout of Lineage Histories and Gene Expression Profiles in Single Cells. (amedeo.com)
  • Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34+ cord blood hematopoietic stem cells using a clinically applicable lentiviral vector. (amedeo.com)
  • This could potentially replace current mobilization regimens that rely on ex vivo gene therapy approaches to treat genetic diseases. (businesswire.com)
  • The research lab of Louis M. Pelus, PhD focuses on understanding the regulation of survival proliferation and differentiation of normal adult blood and mesenchymal stem cells, how they respond to stress, and how this knowledge can be leveraged for therapeutic application in the areas of bone marrow transplantation, gene therapy and protection and mitigation of radiation injury. (iu.edu)
  • Regulation of hematopoietic stem cell release, migration, and homing from the bone marrow (BM) and of the mobilization pathway involves a complex interaction among adhesion molecules, cytokines, proteolytic enzymes, stromal cells, and hematopoietic cells. (hindawi.com)
  • No change in plasma levels of IL-8 or Flt3 ligand was observed, suggesting that these cytokines do not play a role in stem cell mobilization. (rug.nl)
  • Thus far, it is unknown how individual HSC clones migrate and distribute among skeletal niches after transplantation and how this is affected by mobilization-inducing cytokines. (rupress.org)
  • Studies are currently underway to determine the differences between GRO beta and G-CSF mobilized stem cells, the intracellular and extracellular events initiated by GRO beta -CXCR2 interaction that leads to migration of stem cells and how this is regulated, and how combination therapy with other cytokines, chemokines and their receptors can define new paradigms for stem cell transplantation. (iu.edu)
  • It may exert its beneficial effects through neuroprotective and -regenerative activities, mobilization of hematopoietic stem cells and regulation of pro- and anti-inflammatory cytokines as well as angiogenic factors. (frontiersin.org)
  • Platelets are instrumental in the mobilization and differentiation of hematopoietic stem cells at the site of a vascular injury. (einthovenlaboratory.com)
  • The major focus of Dr. Abkowitz s research is understanding the molecular and cellular events that control red cell differentiation. (washington.edu)
  • A heme export protein is required for red blood cell differentiation and iron homeostasis. (washington.edu)
  • Hematopoiesis involves a series of differentiation steps from one progenitor cell to a more committed cell type, forming the recognizable tree seen in the adjacent diagram. (wikipedia.org)
  • Totipotent hematopoietic stem cells: Normal self‐renewal and differentiation after transplantation between mouse fetuses. (currentprotocols.com)
  • Survivin is required for mouse and human mesenchymal stem cell proliferation, survival and differentiation. (iu.edu)
  • The G-CSF-receptor is present on precursor cells in the bone marrow , and, in response to stimulation by G-CSF, initiates proliferation and differentiation into mature granulocytes . (wikipedia.org)
  • The identification of new mechanisms that regulate the trafficking of hematopoietic stem/progenitor cells (HSPCs) cells has important implications, not only for hematopoietic transplantation but also for cell therapies in regenerative medicine for patients with acute myocardial infarction, spinal cord injury, and stroke, among others. (hindawi.com)
  • Distinct hematopoietic stresses thus induce EMH through different mechanisms. (jci.org)
  • The present article reviews some of the key mechanisms mediating HSC mobilization, highlighting recent advances and controversies in the field. (hoggattlab.com)
  • In this review, we will discuss the stem cell mobilizing activities and mechanisms of action of GROβ, a CXC chemokine ligand for the CXCR2 receptor. (elsevier.com)
  • Hematopoietic stem cells in the blood after stem cell factor and interleukin‐11 administration: Evidence for different mechanisms of mobilization. (currentprotocols.com)
  • IL-6, corticosteroids) in tissue regeneration, and defining mobilisation/homing mechanisms and the therapeutic potential of stem cells to improve healing processes after severe trauma. (uni-ulm.de)
  • 1.5 x 10 6 CD34+ cells are collected, patients undergo a second day of apheresis. (confex.com)
  • A total of 15.3, 5.6, and 9.0 x 10 6 CD34+ cells/kg were collected in a single day of apheresis, and no subsequent apheresis or mobilization was required. (confex.com)
  • The mobilization and apheresis procedures had an acceptable toxicity profile. (confex.com)
  • On day 5, daily apheresis started and was continued for up to 4 days, or until ≥ 5 × 10 6 CD34+ cells/kg was collected. (springer.com)
  • In the GP arm, 9/16 patients (56.3%) achieved collection of ≥ 5 × 10 6 CD34+ cells/kg in ≤ 4 days of apheresis, while 1/16 patient (6.3%) achieved this target in the G arm. (springer.com)
  • The yield of MNCs and CD34+ cells per milliliter of blood collected via apheresis was significantly greater in the PEG group than that in the FIL group (P = 0.014 and P = 0.038). (bvsalud.org)
  • However, the total cost of mobilization and apheresis using PEG or FIL was comparable (P = 0.486). (bvsalud.org)
  • After mobilization, participants will undergo a procedure called apheresis to remove the white blood cells. (clinicaltrials.gov)
  • The cells will be recollected from peripheral blood by apheresis and refrigerated. (bioportfolio.com)
  • The cells are collected from the peripheral blood using an apheresis device, which acts like a centrifuge to remove whole blood from the donor and separate its components. (aabb.org)
  • To increase the number of circulating progenitor cells collected, prior to apheresis the donor/patient is prepared or 'mobilized' using recombinant hematopoietic growth factor administration. (aabb.org)
  • Hematopoietic stem cell transplantation, which replaces abnormal blood-forming stem cells with healthy cells, is a curative treatment for a variety of blood and immune disorders. (news-medical.net)
  • Better harvesting protocols would significantly improve the success rate for current indications and open curative hematopoietic cell therapies to a wider spectrum of disorders,' Forsberg says. (news-medical.net)
  • Hematopoietic cell transplantation (HCT) is the only curative option for various neoplastic and a few non-neoplastic diseases. (haematologica.org)
  • Hematopoietic stem cell transplantation (HSCT) is a curative treatment for life-threatening malignancies and related diseases. (bioportfolio.com)
  • The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. (semanticscholar.org)
  • BACKGROUND: Liver regeneration is a heterogeneous phenomenon involving the proliferation of different cell lineages in response to injury. (unicatt.it)
  • With the increasing diversity of stem cell sources emerging for donor cells in transplantation therapy, many laboratory-to-clinic translational factors must first be considered, dynamics such as the source of the cells, ease of extraction, immunogenicity, capacity for proliferation, and cell yield. (mdpi.com)
  • Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. (amedeo.com)
  • Survivin modulates genes with divergent functions and regulates proliferation of hematopoietic stem cells through Evi-1. (iu.edu)
  • Mobilized hematopoietic stem cells are suitable for the bone marrow transplantation in leukemias such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocyte leukemia, Hairy cell leukemia, etc. (ac.ir)
  • We investigate bone marrow stem cell migration to the liver in patients undergoing hepatectomy or with acute on chronic liver failure. (unicatt.it)
  • CONCLUSIONS: Bone marrow derived cell mobilization can not be detected after hepatectomy or during an acute decompensation on a cirrhotic liver. (unicatt.it)
  • Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. (bioportfolio.com)
  • Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation. (bioportfolio.com)
  • Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. (semanticscholar.org)
  • Aetna considers natalizumab experimental and investigational for all other indications (e.g., acute ischemic stroke, chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, Rasmussen encephalitis, stem cell mobilization, and ulcerative colitis) because its effectiveness for indications other than the ones listed above has not been established. (aetna.com)
  • PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome. (iu.edu)
  • Long-term hematopoietic stem cell damage in a murine model of the hematopoietic syndrome of the acute radiation syndrome. (iu.edu)
  • Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. (iu.edu)
  • In patients with acute myeloid leukemia (AML), the production of healthy blood cells from hematopoietic stem cells in the bone marrow (a process called hematopoiesis) is suppressed, prompting the need for bone marrow transplants. (sciencemag.org)
  • Using the prostaglandin signaling cascade to mitigate the effects of acute and delayed radiation exposure to hematopoiesis and blood cell function. (iu.edu)
  • The use of the biosimilar tbo-filgrastim for mobilization in either autologous or allogeneic HSCT has comparable outcomes to that of the biotherapeutic reference product filgrastim at a reduced cost. (mdedge.com)
  • The ability of IL-33 to promote migration of HSPCs and myeloid cells into the periphery and to regulate their antifungal activity represents a previously unrecognized role of IL-33 in innate immunity. (jimmunol.org)
  • Journal Article] Mortalin and DJ-1 coordinately regulate hematopoietic stem cell function through the control of oxidative stress. (nii.ac.jp)
  • Journal Article] Jam1a-Jam2a interactions regulate haematopoietic stem cell fate through Notch signalling. (nii.ac.jp)
  • The mechanism whereby DM impairs stem cell mobilization may depend on altered local concentrations of the chemokine SDF-1α. (diabetesjournals.org)
  • In conclusion, autonomic neuropathy in the BM impairs stem cell mobilization in diabetes with dysregulation of the life-span regulators p66Shc and Sirt1 . (diabetesjournals.org)
  • Developing more efficacious HPC mobilization regimens and strategies may enhance the mobilization process and improve patient outcome. (haematologica.org)
  • Autologous stem cells are acquired from the host in which the cells are intended for use, while allogenic cells are procured from an unrelated donor prior to transplantation. (mdpi.com)
  • AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. (semanticscholar.org)
  • This review is intended as a basic overview of allogeneic and autologous stem cell transplantation with a special focus on long-term follow-up issues relevant to primary care providers. (cmaj.ca)
  • Mass cytometry (CyTOF) was used to analyze ex vivo cultured CD34+ cells with over 35 cell surface markers. (confex.com)
  • Catlin SN, Busque L, Gale R, Guttorp P and Abkowitz JL The replication rate of human hematopoietic stem cells in vivo. (washington.edu)
  • We also evaluated in vivo the proangiogenic capacity of peripheral blood mononuclear cells using the Matrigel plug assay. (diabetesjournals.org)
  • The in vivo angiogenic capacity of peripheral blood mononuclear cells significantly increased after hrG-CSF in control subjects without DM, but not in patients with DM. (diabetesjournals.org)
  • Chimeric contribution of human extended pluripotent stem cells to monkey embryos ex vivo. (amedeo.com)
  • These attributes are complemented by sophisticated, clinically relevant in vitro and in vivo models of the trauma impact and resulting complications to gain deep insights into the mechanistic complexity and regeneration potential post trauma as well as to evaluate innovative cell- and molecular based therapies. (uni-ulm.de)
  • In the long-term perspective, a valid functional immune monitoring of the individual danger response on the background of various co-morbidities and adapted immune- and cell-based therapies, for example by complement intervention and large-scale GMPgrade cellular ex vivo expansion, are anticipated. (uni-ulm.de)
  • Enzymatic cleavage of neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells. (iu.edu)
  • This suggests that SCF and c-Kit plays an important role in hematopoietic function in adulthood. (wikipedia.org)
  • Here, we report that the degradation of BM stromal cell-derived factor (SDF-1) by matrix metalloproteinase (MMP)-9 is important in G-CSF-mediated hematopoietic stem/progenitor cells (HSPCs) mobilization. (qxmd.com)
  • Carboxypeptidase M expressed by human bone marrow cells cleaves the C-terminal lysine of stromal cell-derived factor-1alpha: another player in hematopoietic stem/progenitor cell mobilization? (qxmd.com)
  • Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population. (cdc.gov)
  • It is adjacent to stromal cells that secrete ligands, such as stem cell factor (SCF). (wikidoc.org)
  • A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. (biomedsearch.com)
  • Autologous peripheral hematopoietic stem cell transplantation (APHSCT) was performed to treat a patient with neuromyelitis optica. (biomedsearch.com)
  • This study specifically refers to the 1,000th hematopoietic stem cell transplantation (HSCT) procedure conducted for multiple sclerosis (MS), neuromyelitis optica (NMO) ankylosing spondylitis, chronic inflammatory demyelinating polyneuropathy (CIDP), and transverse myelitis, at the HSCT-México program in both campuses, Clínica Ruiz in Puebla and Clínica Gómez Almaguer in Monterrey. (frontiersin.org)
  • and the number of contaminated T cells was considered too high for safe allogeneic transplantation [ 1 ]. (hindawi.com)
  • Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation: IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). (currentprotocols.com)
  • Stem cell transplantation can be performed with cells from a family member or an unrelated volunteer (allogeneic transplantation) or with stem cells previously collected from the patient (autologous transplantation). (cmaj.ca)
  • Allogeneic transplantation represents 40% of all stem cell transplants performed annually in Canada and requires donor and recipient matching for major histocompatibility (HLA) antigens. (cmaj.ca)
  • Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. (prnewswire.com)
  • Peripheral Blood Progenitor Cells (PBPCs) are another type of cell therapy product that contains HPCs. (aabb.org)
  • OBJECTIVE Diabetes mellitus (DM) increases cardiovascular risk, at least in part, through shortage of vascular regenerative cells derived from the bone marrow (BM). (diabetesjournals.org)
  • Diabetes mellitus (DM) increases cardiovascular disease, and this is attributed, at least in part, to shortage of vascular regenerative cells derived from the bone marrow (BM) ( 1 ). (diabetesjournals.org)
  • We have previously shown that DM prevents postischemic progenitor cell mobilization in rats, which translates into impaired vascular recovery after ischemia ( 3 ). (diabetesjournals.org)
  • We hypothesize that neuropathy of the BM affects stem cell mobilization and vascular recovery after ischemia in patients with diabetes. (diabetesjournals.org)
  • Hematopoietic Sirt1 KO mimicked the diabetic mobilization defect, whereas hematopoietic Sirt1 overexpression in diabetes rescued defective mobilization and vascular repair. (diabetesjournals.org)
  • Our data show that denervation in the diabetic BM is mediated by the 66-kDa protein from the src homology and collagen homology domain ( p66Shc ) and that impaired mobilization relies on sirtuin 1 ( Sirt1 ) dysregulation, both of which are therefore potential targets to restore BM cell-mediated vascular repair. (diabetesjournals.org)
  • Even greater advantage in repopulation and restoration of hematopoiesis are observed with stem cells mobilized by the combination of GROβ and G-CSF. (elsevier.com)
  • There are 2 types of hematopoiesis that occur in humans: Primitive hematopoiesis - blood stem cells differentiate into only a few specialized blood lineages (typically isolated to early fetal development). (wikipedia.org)
  • The pioneering work of Till and McCulloch in 1961 experimentally confirmed the development of blood cells from a single precursor hematopoietic stem cell (HSC), creating the framework for the field of hematopoiesis to be studied over the following decades. (wikipedia.org)
  • This cytokine plays an important role in hematopoiesis (formation of blood cells), spermatogenesis, and melanogenesis. (wikipedia.org)
  • The stem cells are then able to travel or "home" to the bone marrow cavity to re-establish hematopoiesis over the next 2 weeks. (cmaj.ca)
  • The laboratory has identified GRO beta, a member of a family of peptides called chemokines, which stimulates the migration of stem cells that are able to completely reconstitute hematopoiesis from bone marrow to blood. (iu.edu)
  • Interleukin‐8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long‐term myelolymphoid repopulating ability. (currentprotocols.com)
  • Major barriers to using hematopoietic stem cell transplantation include the limited supply of donor cells and the lack of efficient means to harvest them. (news-medical.net)
  • transplantation in an allogeneic setting provides immune tolerance to donor cells, thereby allowing donor T cells to mediate a graft‐versus‐tumor or graft‐versus‐leukemia effect. (researchpad.co)
  • However, it is difficult to predict mobilization failure in an individual donor, because poor mobilization is observed even in patients lacking high‐risk characteristics. (researchpad.co)
  • These concerns may serve as potential limitations respective to the donor cell origin being considered, proving a particular source to be a more suitable therapy for a specific disease. (mdpi.com)
  • Blood enters the machine and is processed so that the HPCs and other white blood cells are removed, while the remainder of the blood is returned to the donor through a second needle placed in the other arm. (aabb.org)
  • Blood stem cell transplantation is accomplished by treating the donor with hematopoietic growth factors, which cause the stem cells to proliferate and circulate freely in the peripheral blood. (cmaj.ca)
  • Fig. 1: Collection of stem cells by direct aspiration from bone marrow, with the donor under general anesthetic. (cmaj.ca)
  • G-CSF is also used to increase the number of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell transplantation . (wikipedia.org)
  • Hematopoietic stem and progenitor cells (HSPCs) continuously egress out of the bone marrow (BM) to the circulation under homeostatic conditions. (stembook.org)
  • MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. (qxmd.com)
  • Recently, a novel hematopoietic stem cell (HSC)-based strategy has been tested in individuals with new-onset T1D. (diabetesjournals.org)
  • Globally, our results indicate that although osteoclast-dependent HSC mobilization from bone marrow to spleen is triggered in murine blood stage malaria, this activity is not essential for stress erythropoiesis. (hindawi.com)
  • Plasticity of murine hematopoietic stem cells, 1999. (cincinnatichildrens.org)
  • To investigate the changes and mechanism of angiopoietin1 (Ang1) in murine bone marrow during G-CSF induced mobilization of hematopoietic stem / progenitor cell . (bvsalud.org)
  • As examples, she is investigating heme signaling and the molecular consequences of excess heme with single cell RNA seq studies of murine models and MDS patient morrow samples. (washington.edu)
  • If proven safe and effective in human clinical studies, 'clinicians could consider these findings when selecting treatment strategies for their patients and for volunteer donors of hematopoietic cells used in transplantation therapies. (news-medical.net)
  • and (d) the effects of this mobilization on BM-derived stem/progenitor cells in clinical trials of patients with different diseases. (hindawi.com)
  • 1 The vast majority of clinical autologous HCT procedures utilize hematopoietic progenitor cells (HPCs) mobilized into the blood. (haematologica.org)
  • These properties of IL-33 have clinical implications in hematopoietic stem cell transplantation. (jimmunol.org)
  • The major source for clinical transplantation protocols is via peripheral blood (PB) mobilization of BM derived HSPCs. (stembook.org)
  • Group B patients then proceed to BMH to obtain cells for clinical DP manufacture. (confex.com)
  • Our findings have important implications for experimental and clinical and stem cell transplantation protocols. (rupress.org)
  • In addition, GROβ may also have clinical mobilizing efficacy on its own, reducing the overall time and costs associated with peripheral blood stem cell transplantation. (elsevier.com)
  • Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees. (bioportfolio.com)
  • This review will discuss the current knowledge of stem cell research in neurological disease, mainly stroke, with a focus on the benefits, limitations, and clinical potential. (mdpi.com)
  • The objectives of this proposal are to run a phase II clinical trial to assess the safety and efficacy of NSAIDs with G-CSF for autologous mobilization in patients with MM and NHL and molecularly characterize the NSAID assisted graft. (iu.edu)
  • Hematopoietic stem cell numbers and cytokine levels are altered by ongoing G-CSF application and may potentially serve as treatment biomarkers for early monitoring of G-CSF treatment efficacy in ALS in future clinical trials. (frontiersin.org)
  • Here, we performed a real-world analysis to evaluate the efficacy and cost of PEG for mobilization in a cohort of MM patients , of which 53% carried high- risk cytogenetic abnormalities . (bvsalud.org)
  • The efficacy and rapid action of GROβ and lack of proinflammatory activity make it an attractive agent to supplement mobilization by G-CSF. (elsevier.com)
  • In addition to analyzing the viability, safety, and efficacy of our method, this study contributes new knowledge to the field of both stem cell transplantation and multiple sclerosis. (frontiersin.org)
  • Most of the data on the mobilization efficacy and safety of biosimilar G-CSF are from adult patients, whereas no data are available in pediatric patients. (wiley.com)
  • Despite use of newer approaches, some patients being considered for autologous hematopoietic cell transplantation (HCT) may only mobilize limited numbers of hematopoietic progenitor cells (HPCs) into blood, precluding use of the procedure, or being placed at increased risk of complications due to slow hematopoietic reconstitution. (haematologica.org)
  • HPCs are capable of forming mature blood cells, such as red blood cells (the cells that carry oxygen), platelets (the cells that help stop bleeding) and white blood cells (the cells that fight infections). (aabb.org)